85. 特発性間質性肺炎 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 627 / 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212
薬物ごとの開発者(Primary Sponsor)、臨床試験情報(抜粋)です。
(18)F-FDG
Medizinische Universität Wien, Univ.Klinik f.Radiodiagnostik
2010 - EUCTR2010-020223-44-AT Austria;
00258901
F. HOFFMANN - LA ROCHE LTD.
2016 Phase 2 EUCTR2015-005131-40-IT Belgium;Canada;Czech Republic;Czechia;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
00322900
F. HOFFMANN - LA ROCHE LTD.
2016 Phase 2 EUCTR2015-005131-40-IT Belgium;Canada;Czech Republic;Czechia;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
18F-FDG
Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui
2007 - JPRN-UMIN000010498 Japan;
3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt
Vicore Pharma AB
2020 Phase 2 EUCTR2020-000822-24-GB Ukraine;United Kingdom;
534-1508
F. Hoffmann-La Roche Ltd
2016 Phase 4 EUCTR2015-003280-11-NL Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
2016 Phase 4 EUCTR2015-003280-11-DK Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
2016 Phase 4 EUCTR2015-003280-11-DE Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
Roche Farma S.A., que representa en España a F. Hoffmann-La Roche Ltd
2015 Phase 4 EUCTR2015-003280-11-ES Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
68Ga-BMV101
Peking Union Medical College Hospital
2015 Early Phase 1 NCT02485886 China;
ACT-064992
ACTELION Pharmaceuticals Ltd.
2011 - EUCTR2010-024211-13-SI Australia;Canada;Germany;Israel;Slovenia;South Africa;Spain;Sweden;Turkey;United States;
2011 - EUCTR2010-024211-13-SE Australia;Canada;Germany;Israel;South Africa;Spain;Sweden;Turkey;United States;
2011 - EUCTR2010-024211-13-ES Australia;Canada;Germany;Israel;South Africa;Spain;Sweden;Turkey;United States;
2011 - EUCTR2010-024211-13-DE Australia;Canada;Germany;Israel;South Africa;Spain;Sweden;Turkey;United States;
Actelion Pharamceuticals Ltd
2010 - EUCTR2008-006054-17-IT France;Germany;Italy;Slovenia;Spain;Sweden;
Actelion Pharmaceuticals Ltd.
2009 Phase 2 EUCTR2008-006054-17-ES France;Germany;Italy;Slovenia;Spain;Sweden;
2009 - EUCTR2008-006054-17-SI France;Germany;Italy;Slovenia;Spain;Sweden;
2009 - EUCTR2008-006054-17-SE France;Germany;Italy;Slovenia;Spain;Sweden;
2009 - EUCTR2008-006054-17-FR France;Germany;Italy;Slovenia;Spain;Sweden;
- - EUCTR2008-006054-17-DE France;Germany;Italy;Slovenia;Spain;Sweden;
ACT-064992 (macitentan)
Actelion
2009 Phase 2 NCT00903331 Australia;Canada;France;Germany;Israel;Italy;Slovenia;South Africa;Spain;Sweden;Turkey;United States;
AP01
Avalyn Pharma, Inc.
2021 Phase 2 EUCTR2020-005103-39-PL Australia;Czech Republic;Czechia;Netherlands;New Zealand;Poland;United Kingdom;
2021 Phase 2 EUCTR2020-005103-39-CZ Australia;Czech Republic;Czechia;Netherlands;New Zealand;Poland;United Kingdom;
ART-123
ASAHI KASEI PHARMA CORPORATION
2016 Phase 3 JPRN-JapicCTI-163326 -
Asahi Kasei Pharma Corporation
2016 Phase 3 NCT02739165 Japan;
AT 10
Makino Ryoko
2021 Phase 3 JPRN-jRCT2051210129 Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;South Korea;Spain;Sweden;
AZAPRED
Thorax National Institute
2005 - NCT00518310 Chile;
AZD5055
AstraZeneca
2021 Phase 1 NCT05134727 United States;
Acetylcysteine
Saitama Red Cross Hospital
2013 - JPRN-UMIN000016706 Japan;
Shanghai Pulmonary Hospital, Tongji University School of Medicine
2020 - ChiCTR2000031386 China;
Aerosol interferon-gamma
NYU Langone Health
2007 Phase 1 NCT00563212 United States;
Air
Department of Respiratory Medicine, Toho University Omori Medical Center, Tokyo
2009 - JPRN-UMIN000016045 Japan;
Grant for Research on Diffuse Lung Disease from the Ministry of Health, Labour and Welfare of Japan.
2015 - JPRN-UMIN000015508 Japan;
Alemtuzumab
Paul Szabolcs
2018 Phase 1/Phase 2 NCT03500731 United States;
AlloRx
The Foundation for Orthopaedics and Regenerative Medicine
2022 Phase 1 NCT05016817 Antigua and Barbuda;
Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)
Joshua M Hare
2013 Phase 1 NCT02013700 United States;
Ambrisentan
Gilead Sciences
2009 Phase 3 NCT00879229 Australia;Austria;Belgium;Canada;Germany;Ireland;Israel;Italy;United Kingdom;United States;
2008 Phase 3 NCT00768300 Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;France;Germany;Ireland;Israel;Italy;Mexico;Netherlands;Peru;Poland;Spain;Switzerland;United Kingdom;United States;
Gilead Sciences Incorporated
2010 - EUCTR2008-004405-34-CZ Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-004405-34-FR Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-004405-34-NL Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-004405-34-IT Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-004405-34-IE Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-004405-34-GB Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-004405-34-ES Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-004405-34-BE Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-004405-34-AT Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
- - EUCTR2008-004405-34-DE Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
Gilead Sciences, Inc
2009 - EUCTR2009-011169-98-GB Austria;Czech Republic;Germany;Italy;United Kingdom;
2009 - EUCTR2009-011169-98-DE Austria;Czech Republic;Germany;Italy;United Kingdom;
2009 - EUCTR2009-011169-98-AT Austria;Czech Republic;Germany;Italy;United Kingdom;
Gilead Sciences, Inc.
2011 - EUCTR2009-011169-98-CZ Austria;Czech Republic;Germany;Italy;United Kingdom;
Antimicrobial therapy: Co-trimoxazole or Doxycycline
Weill Medical College of Cornell University
2017 Phase 3 NCT02759120 United States;
Atezolizumab
KATO Terufumi
2019 Phase 2 JPRN-jRCTs031190084 Japan;
Auto-titrating oxygen system
Imperial College London
2014 - NCT02248064 United Kingdom;
Autoantibody Reductive Therapy
University of Alabama at Birmingham
2018 Phase 2 NCT03286556 United States;
Autologous Adipose Derived MSCs (ADMSCs)
Kasiak Research Pvt. Ltd.
2014 Phase 1/Phase 2 NCT02135380 India;
Autologous Stromal Vascular Fraction (SVF)
Kasiak Research Pvt. Ltd.
2014 Phase 1/Phase 2 NCT02135380 India;
Autologous mesenchymal stem cells derived from bone marrow
Clinica Universidad de Navarra, Universidad de Navarra
2013 Phase 1 NCT01919827 Spain;
Aviptadil, 66 microgram/mL
Mondobiotech Laboratories Anstalt
2006 - EUCTR2006-002174-22-DE Germany;
Azathioprine
InterMune
2002 Phase 3 NCT00052039 Italy;
Azathioprine/prednisone
University of Michigan
2001 Phase 2 NCT00262405 United States;
Azithromycin
Maisonneuve-Rosemont Hospital
2011 Phase 2 NCT01432080 Canada;
University Hospital Inselspital, Berne
2014 - NCT02173145 Switzerland;
BBT-877, Multiple doses
Bridge Biotherapeutics, Inc.
2019 Phase 1 NCT03830125 United States;
BBT-877, Single dose
Bridge Biotherapeutics, Inc.
2019 Phase 1 NCT03830125 United States;
BG00011
BIOGEN IDEC RESEARCH LIMITED
2018 Phase 2 EUCTR2017-003158-18-IT Argentina;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
Biogen
2018 Phase 2 NCT03573505 Argentina;Australia;Belgium;Chile;Czechia;Denmark;France;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2012 Phase 2 NCT01371305 United States;
Biogen Idec Research Limited
2019 Phase 2 EUCTR2017-003158-18-PL Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2019 Phase 2 EUCTR2017-003158-18-DE Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003158-18-NL Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003158-18-GR Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003158-18-GB Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003158-18-ES Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003158-18-DK Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003158-18-CZ Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003158-18-BE Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
BI 1015550
BOEHRINGER-INGELHEIM ITALIA S.P.A.
2020 Phase 2 EUCTR2019-004167-45-IT Australia;Austria;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Boehringer Ingelheim
2020 Phase 2 NCT04419506 Argentina;Australia;Austria;Canada;Chile;China;Czechia;Denmark;Finland;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004167-45-NL Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2018 Phase 1 NCT03422068 Belgium;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;United Kingdom;
Boehringer Ingelheim B.V.
2020 Phase 2 EUCTR2019-004167-45-DK Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Boehringer Ingelheim Finland Ky
2020 Phase 2 EUCTR2019-004167-45-FI Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Boehringer Ingelheim Limited
2020 Phase 2 EUCTR2019-004167-45-GB Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co. KG
2020 Phase 2 EUCTR2019-004167-45-DE Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Boehringer Ingelheim RCV GmbH & Co KG
2021 Phase 2 EUCTR2019-004167-45-CZ Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004167-45-SK Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004167-45-PL Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004167-45-HU Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004167-45-AT Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
BIBF 1120
BOEHRINGER ING.
2012 Phase 3 EUCTR2011-002766-21-IT Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
2011 - EUCTR2010-024251-87-IT Belgium;Czech Republic;Germany;Ireland;Italy;United Kingdom;
2010 Phase 2 EUCTR2009-013788-21-IT Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim
2012 Phase 3 NCT01619085 Australia;Belgium;Canada;Chile;China;Czech Republic;Czechia;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
2012 Phase 3 EUCTR2011-002766-21-FI Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
2011 Phase 3 NCT01335477 Canada;Chile;China;Finland;France;Germany;Greece;India;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United States;
2011 Phase 3 NCT01335464 Argentina;Australia;Belgium;Brazil;China;Czech Republic;France;Germany;India;Ireland;Israel;Italy;Japan;United Kingdom;United States;
2011 - EUCTR2010-024252-29-NL Finland;Germany;Greece;Netherlands;Portugal;Spain;
2011 - EUCTR2010-024252-29-GR Finland;Germany;Greece;Netherlands;Portugal;Spain;
2011 - EUCTR2010-024252-29-FI Finland;Germany;Greece;Netherlands;Portugal;Spain;
2010 Phase 2 NCT01170065 Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;El Salvador;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;
2010 Phase 2 NCT01136174 Japan;
2008 - EUCTR2006-002875-42-GR Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2007 Phase 2 EUCTR2006-002875-42-GB Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2007 - EUCTR2006-002875-42-IE Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2007 - EUCTR2006-002875-42-DE Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
Boehringer Ingelheim Hellas
2012 Phase 3 EUCTR2011-002766-21-GR Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
Boehringer Ingelheim Ellas AE
2010 - EUCTR2009-013788-21-GR Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim España S.A
2012 Phase 3 EUCTR2011-002766-21-ES Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
Boehringer Ingelheim España S.A.
2010 - EUCTR2009-013788-21-ES Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim España, S.A.
2011 Phase 3 EUCTR2010-024252-29-ES Canada;Chile;China;Finland;France;Germany;Greece;India;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United States;
2007 - EUCTR2006-002875-42-ES Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
Boehringer Ingelheim France
2011 - EUCTR2010-024252-29-PT Canada;China;Finland;France;Germany;Greece;India;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;United States;
2010 Phase 2 EUCTR2009-013788-21-FR Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
2008 - EUCTR2006-002875-42-PT Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
Boehringer Ingelheim France SAS
2007 Phase 2 EUCTR2006-002875-42-FR Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
Boehringer Ingelheim Limited
2013 Phase 3 EUCTR2011-002766-21-IE Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
2012 Phase 3 EUCTR2011-002766-21-GB Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
2011 Phase 3 EUCTR2010-024251-87-GB Belgium;Czech Republic;Germany;Ireland;Italy;United Kingdom;
2011 - EUCTR2010-024251-87-IE Belgium;Czech Republic;Germany;Ireland;Italy;United Kingdom;
2010 Phase 2 EUCTR2009-013788-21-GB Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim Ltd
2010 Phase 2 EUCTR2009-013788-21-IE Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim Pharma Ges mbH
2008 - EUCTR2006-002875-42-BG Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2007 - EUCTR2006-002875-42-CZ Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
Boehringer Ingelheim Pharma GmbH & Co. KG
2012 Phase 3 EUCTR2011-002766-21-DE Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
2011 - EUCTR2010-024252-29-DE Canada;Chile;China;Finland;France;Germany;Greece;India;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United States;
2011 - EUCTR2010-024251-87-DE Argentina;Australia;Belgium;Brazil;China;Czech Republic;France;Germany;India;Ireland;Israel;Italy;Japan;United Kingdom;United States;
2010 Phase 2 EUCTR2009-013788-21-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;
Boehringer Ingelheim RCV Ges mbH & Co KG
2007 - EUCTR2006-002875-42-HU Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
Boehringer Ingelheim RCV GmBH & Co KG
2011 - EUCTR2010-024251-87-CZ Argentina;Australia;Belgium;Brazil;China;Czech Republic;Germany;India;Ireland;Israel;Italy;Japan;United Kingdom;United States;
2010 Phase 2 EUCTR2009-013788-21-HU Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
2010 - EUCTR2009-013788-21-BG Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim RCV GmbH & Co KG
2012 Phase 3 EUCTR2011-002766-21-CZ Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
2010 Phase 2 EUCTR2009-013788-21-CZ Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Russian Federation;Spain;United Kingdom;
Boehringer Ingelheim bv
2007 - EUCTR2006-002875-42-NL Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
SCS Boehringer Ingelheim Comm.V
2011 Phase 3 EUCTR2010-024251-87-BE Argentina;Australia;Belgium;Brazil;China;Czech Republic;France;Germany;India;Ireland;Israel;Italy;Japan;United Kingdom;United States;
2010 Phase 2 EUCTR2009-013788-21-BE Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
2007 - EUCTR2006-002875-42-BE Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
SCS Boehringer Ingelheim Ingelheim Comm.V
2012 Phase 3 EUCTR2011-002766-21-BE Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
Unilfarma - União Internacional de Lab. Farmacêuticos, Lda
2012 Phase 3 EUCTR2011-002766-21-PT Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
Unilfarma, Lda.
2010 Phase 2 EUCTR2009-013788-21-PT Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
BIBF 1120 ES
BOEHRINGER ING.
2007 - EUCTR2006-002875-42-IT Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
BIBF1120
Boehringer Ingelheim España, S.A.
2011 Phase 3 EUCTR2010-024252-29-ES Canada;Chile;China;Finland;France;Germany;Greece;India;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United States;
BLD-2660
Blade Therapeutics
2019 Phase 2 NCT04244825 United Kingdom;
Blade Therapeutics, Inc.
2020 Phase 2 EUCTR2019-004998-34-GB United Kingdom;
BMS-986020
Bristol-Myers Squibb
2013 Phase 2 NCT01766817 Australia;Chile;Colombia;Mexico;Peru;United States;
BMS-986278
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2020 Phase 2 EUCTR2019-003992-21-IT Argentina;Australia;Belgium;Brazil;Canada;Chile;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Spain;Taiwan;United Kingdom;United States;
Bristol-Myers Squibb
2019 Phase 1 NCT03981094 United States;
Bristol-Myers Squibb International Corporation
2020 Phase 2 EUCTR2019-003992-21-DE Argentina;Australia;Belgium;Brazil;Canada;Chile;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003992-21-BE Argentina;Australia;Belgium;Brazil;Canada;Chile;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Bardoxolone methyl
Reata Pharmaceuticals, Inc.
2014 Phase 2 NCT02036970 Germany;Spain;United Kingdom;United States;
Beclometasone dipropionate
Hull and East Yorkshire Hospitals NHS Trust
2014 - EUCTR2013-004404-19-GB United Kingdom;
Bevacizumab
IP lung cancer study group
2012 - JPRN-UMIN000018322 Japan;
Katakami Nobuyuki
2013 Phase 2 JPRN-jRCTs061180046 Japan;
Blood sample collection
Rennes University Hospital
2014 - NCT04016168 France;
Bone marrow mesenchymal stem cells
Federal Research Clinical Center of Federal Medical & Biological Agency, Russia
2013 Phase 1/Phase 2 NCT02594839 Russian Federation;
Bosentan
Actelion
2008 Phase 3 NCT00631475 Australia;Austria;Belgium;Canada;Croatia;Czech Republic;Former Serbia and Montenegro;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Serbia;Spain;Switzerland;United Kingdom;United States;
2007 Phase 3 NCT00391443 Australia;Austria;Belgium;Canada;Croatia;Czech Republic;Denmark;Former Serbia and Montenegro;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Serbia;Slovakia;Spain;Switzerland;United Kingdom;United States;
2003 Phase 2/Phase 3 NCT00071461 Canada;France;Germany;Israel;Italy;Switzerland;United Kingdom;United States;
Actelion Registration Ltd
2008 - EUCTR2007-001741-18-IT Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
Department of Respiratory Medicine, Chiba-Hokusoh Hospital, Nippon Medical School
2011 - JPRN-UMIN000004749 Japan;
Rajan Saggar
2007 Phase 4 NCT00625469 United States;
Royal Brompton & Harefield NHS Foundation Trust
2008 Phase 4 NCT00637065 United Kingdom;
Broncho-Vaxom
Shanghai Pulmonary Hospital
2015 - ChiCTR-OOC-15005840 China;
Bronchoalveolar lavage (BAL fluid)
McGill University Health Centre/Research Institute of the McGill University Health Centre
2021 - NCT05007340 Canada;
C21
Vicore Pharma AB
2020 Phase 2 NCT04533022 India;Russian Federation;Ukraine;United Kingdom;
2020 Phase 2 EUCTR2020-000822-24-GB Ukraine;United Kingdom;
2018 Phase 2 EUCTR2017-004923-63-GB Bulgaria;Poland;Serbia;United Kingdom;
CBDCA
Lung Oncology Group in Kyushu, Japan (LOGIK)
2007 - JPRN-UMIN000015929 Japan;
CC-90001
Celgene
2017 Phase 2 NCT03142191 Australia;Brazil;Canada;China;Colombia;Germany;Greece;Romania;Russian Federation;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Celgene Corporation
2017 Phase 2 EUCTR2016-003473-17-GR Australia;Brazil;Canada;Colombia;France;Germany;Greece;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003473-17-GB Australia;Brazil;Canada;Colombia;France;Germany;Greece;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
CC-930
Celgene
2011 Phase 2 NCT01203943 Canada;United States;
CD3/CD19 negative hematopoietic stem cells
Paul Szabolcs
2018 Phase 1/Phase 2 NCT03500731 United States;
CNTO 888
Centocor, Inc.
2008 Phase 2 NCT00786201 Belgium;Canada;Germany;Netherlands;United States;
CNTO888
Centocor B.V.
2009 - EUCTR2008-001281-86-NL Belgium;Germany;Netherlands;
Janssen Biologics B.V.
2010 - EUCTR2008-001281-86-DE Belgium;Germany;Netherlands;
2009 Phase 2 EUCTR2008-001281-86-BE Belgium;Germany;Netherlands;
COMPOUND 21
Vicore Pharma AB
2018 Phase 2 EUCTR2017-004923-63-GB Bulgaria;Poland;Serbia;United Kingdom;
CSL312
CSL Behring
2022 Phase 2 NCT05130970 Canada;United States;
Carboplatin
Fujimoto Daichi
2021 - JPRN-jRCTs051200109 Japan;
Hirosaki University Graduate School of Medicine
2016 - JPRN-UMIN000021591 Japan;
IKEDA Satoshi
2019 Phase 2 JPRN-jRCTs031190119 Japan;
IP lung cancer study group
2012 - JPRN-UMIN000018322 Japan;
2012 - JPRN-UMIN000018248 Japan;
Katakami Nobuyuki
2013 Phase 2 JPRN-jRCTs061180046 Japan;
2013 Phase 2 JPRN-jRCTs051180149 Japan;
Lung Oncology Group in Kyushu, Japan (LOGIK)
2007 - JPRN-UMIN000015929 Japan;
Okamoto Isamu
2017 Phase 3 JPRN-jRCTs071180049 Japan;
Research Institute for Diseases of the Chest, Kyushu University
2017 Phase 3 JPRN-UMIN000026799 Japan;
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)
Lung Therapeutics, Inc
2020 Phase 1 NCT04233814 United Kingdom;
Centricyte 1000
Black Tie Medical, Inc.
2020 Early Phase 1 NCT04326036 United States;
Combination Product: EGCG + Nintedanib
Hal Chapman
2022 Phase 1 NCT05195918 United States;
Combination Product: EGCG + Pirfenidone
Hal Chapman
2022 Phase 1 NCT05195918 United States;
Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids
Michael Donahoe
2011 Phase 1/Phase 2 NCT01266317 United States;
Corticosteroid (prednisolone)
Assistance Publique - Hôpitaux de Paris
2015 Phase 3 NCT02460588 France;
Cotrimoxazole
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2013 Phase 3 NCT01777737 Spain;
Norfolk and Norwich University Hospital NHS Foundation Trust
2014 Phase 3 EUCTR2014-004058-32-GB United Kingdom;
Cravit
Respiratory Department, Peking Union Medical College Hospital
2011 - ChiCTR-TRC-12002372 China;
Cromolyn Sodium
University of California, San Francisco
2015 Phase 1 NCT01841307 United States;
Cromolyn sodio (cromoglicato disodico, DSCG)
Respivant Sciences, GmbH
2019 Phase 2 EUCTR2018-004447-23-IT Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
Cromolyn sodium [Disodium Cromoglycate]
Respivant Sciences GmbH
2019 Phase 2 EUCTR2018-004447-23-NL Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004447-23-GB Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004447-23-DE Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;Turkey;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004447-23-CZ Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004447-23-BE Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
Cyclophosphamide
Assistance Publique - Hôpitaux de Paris
2015 Phase 3 NCT02460588 France;
Peking Union Medical College Hospital
2019 Phase 4 ChiCTR1900027121 China;
Cyclosphamine
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2015 Phase 3 EUCTR2015-000492-27-FR France;
DEX284
Galecto Biotech AB
2020 Phase 2 EUCTR2018-002664-73-IE Australia;Belgium;Canada;France;Georgia;Germany;Ireland;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002664-73-PL Australia;Belgium;Canada;France;Georgia;Germany;Ireland;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002664-73-IT Belgium;Canada;France;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002664-73-GB Belgium;Canada;France;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002664-73-FR Belgium;Canada;France;Germany;Israel;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002664-73-ES Belgium;Canada;France;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States;
DWN12088
Daewoong Pharmaceutical Co. LTD.
2021 Phase 1 NCT04888728 Korea, Republic of;
2021 Phase 1 NCT04888715 Korea, Republic of;
Dabigatran
University College, London
2016 - NCT02885961 -
Dasatinib + Quercetin
Wake Forest University Health Sciences
2016 Phase 1 NCT02874989 United States;
Dextromethorphan
Tianjin Medical University General Hospital
2020 Phase 4 ChiCTR2000037602 China;
Diet A group
Daewoong Pharmaceutical Co. LTD.
2021 Phase 1 NCT04767815 Korea, Republic of;
Diet B group
Daewoong Pharmaceutical Co. LTD.
2021 Phase 1 NCT04767815 Korea, Republic of;
Diet C group
Daewoong Pharmaceutical Co. LTD.
2021 Phase 1 NCT04767815 Korea, Republic of;
Disodium Cromoglycate [cromolyn sodium]
Patara Pharma
2015 - EUCTR2014-004025-40-NL Netherlands;United Kingdom;
2014 Phase 2 EUCTR2014-004025-40-GB Netherlands;United Kingdom;
Disodium cromoglycate (DSCG)
Patara Pharma
2015 - EUCTR2014-004025-40-NL Netherlands;United Kingdom;
2014 Phase 2 EUCTR2014-004025-40-GB Netherlands;United Kingdom;
Durvalumab
Fujimoto Daichi
2021 - JPRN-jRCTs051200109 Japan;
ESBRIET - 267 MG - CAPSULA RIGIDA - USO ORALE - FLACONE (HDPE) 270 CAPSULE
F. HOFFMANN - LA ROCHE LTD.
2015 Phase 4 EUCTR2015-003280-11-IT Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
EZ-2053
Neovii Biotech
2005 Phase 3 NCT00105183 Australia;Austria;Canada;United States;
Endobronchial infusion of adult mesenchymal stem cells
Clinica Universidad de Navarra, Universidad de Navarra
2013 Phase 1 NCT01919827 Spain;
Epigallocatechin-3-gallate (EGCG)
University of California, San Francisco
2018 Early Phase 1 NCT03928847 United States;
Erivedge
F. Hoffmann-La Roche Ltd.
2014 - EUCTR2014-000963-42-DE Australia;Chile;France;Germany;Israel;Italy;Korea, Republic of;Mexico;New Zealand;Peru;Spain;United States;
Esbriet
BOEHRINGER-INGELHEIM ITALIA S.P.A.
2015 Phase 4 EUCTR2015-000640-42-IT Canada;France;Germany;Italy;Netherlands;United States;
Boehringer Ingelheim France
2015 Phase 4 EUCTR2015-000640-42-FR Canada;France;Germany;Italy;Netherlands;United States;
Boehringer Ingelheim Pharma GmbH & Co.KG
2015 Phase 4 EUCTR2015-000640-42-DE Canada;France;Germany;Italy;Netherlands;United States;
Boehringer Ingelheim bv
2015 Phase 4 EUCTR2015-000640-42-NL Canada;France;Germany;Italy;Netherlands;United States;
F. Hoffmann-La Roche Ltd
2017 Phase 2 EUCTR2015-005131-40-HU Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2017 Phase 2 EUCTR2015-005131-40-CZ Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 4 EUCTR2015-003280-11-NL Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
2016 Phase 4 EUCTR2015-003280-11-DK Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
2016 Phase 4 EUCTR2015-003280-11-DE Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
2016 Phase 2 EUCTR2015-005131-40-NL Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 2 EUCTR2015-005131-40-GR Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 2 EUCTR2015-005131-40-ES Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 2 EUCTR2015-005131-40-DE Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 2 EUCTR2015-005131-40-BE Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
Roche Farma S.A., que representa en España a F. Hoffmann-La Roche Ltd
2015 Phase 4 EUCTR2015-003280-11-ES Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
Esbriet® (Pirfenidon)
Justus Liebig Universität Giessen
2015 Phase 2 EUCTR2014-000861-32-DE Germany;
Etanercept
Wyeth is now a wholly owned subsidiary of Pfizer
2003 Phase 2 NCT00063869 United States;
Etoposide
Fujimoto Daichi
2021 - JPRN-jRCTs051200109 Japan;
IKEDA Satoshi
2019 Phase 2 JPRN-jRCTs031190119 Japan;
FG-3019
FIBROGEN
2020 Phase 3 EUCTR2020-000697-22-IT Belgium;Brazil;Bulgaria;Colombia;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;India;Ireland;Italy;Lebanon;Mexico;Netherlands;Norway;Peru;Poland;Serbia;Spain;Ukraine;United Kingdom;
FibroGen
2011 Phase 2 NCT01262001 United States;
1994 Phase 1 NCT00074698 United States;
FibroGen, Inc.
2021 Phase 3 EUCTR2020-000697-22-IE Brazil;Colombia;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;Ireland;Italy;Lebanon;Mexico;Netherlands;Peru;Poland;Serbia;Spain;Switzerland;Ukraine;United Kingdom;
2020 Phase 3 EUCTR2020-000697-22-NL Brazil;Colombia;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;Ireland;Italy;Lebanon;Mexico;Netherlands;Peru;Poland;Serbia;Spain;Switzerland;Ukraine;United Kingdom;
2020 Phase 3 EUCTR2020-000697-22-HU Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;India;Ireland;Italy;Lebanon;Mexico;Netherlands;Norway;Peru;Poland;Serbia;Spain;Ukraine;United Kingdom;
2020 Phase 3 EUCTR2020-000697-22-DK Brazil;Colombia;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;Ireland;Italy;Lebanon;Mexico;Netherlands;Peru;Poland;Serbia;Spain;Switzerland;Ukraine;United Kingdom;
2020 Phase 3 EUCTR2020-000697-22-DE Brazil;Colombia;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;Ireland;Italy;Lebanon;Mexico;Netherlands;Peru;Poland;Serbia;Spain;Switzerland;Ukraine;United Kingdom;
FG-3019 10mg/mL in 10 mL vials
FibroGen, Inc.
2016 Phase 2 EUCTR2014-005658-20-BG Australia;Bulgaria;Canada;India;New Zealand;South Africa;United States;
FLUORINE (18F) FLUDEOXYGLUCOSE
Medizinische Universität Wien, Univ.Klinik f.Radiodiagnostik
2010 - EUCTR2010-020223-44-AT Austria;
Fludarabine
Paul Szabolcs
2018 Phase 1/Phase 2 NCT03500731 United States;
Fluimucil® 600 mg effervescent tablets
InterMune International AG.
2013 Phase 2 EUCTR2012-000564-14-GB Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
2013 - EUCTR2012-000564-14-SE Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
2013 - EUCTR2012-000564-14-IT Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
2013 - EUCTR2012-000564-14-DK Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
2013 - EUCTR2012-000564-14-DE Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
2013 - EUCTR2012-000564-14-BE Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
2013 - EUCTR2012-000564-14-AT Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
Formoterol fumarate dihydrate
Hull and East Yorkshire Hospitals NHS Trust
2014 - EUCTR2013-004404-19-GB United Kingdom;
Fostair
Hull University Teaching Hospitals NHS Trust
2014 Phase 2 NCT02048644 United Kingdom;
Hull and East Yorkshire Hospitals NHS Trust
2014 - EUCTR2013-004404-19-GB United Kingdom;
G-CSF
Paul Szabolcs
2018 Phase 1/Phase 2 NCT03500731 United States;
G048E03
F. HOFFMANN - LA ROCHE LTD.
2016 Phase 2 EUCTR2015-005131-40-IT Belgium;Canada;Czech Republic;Czechia;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
G321605
Galapagos NV
2019 Phase 2 EUCTR2017-004302-18-HR Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
2019 Phase 2 EUCTR2017-004302-18-FI Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
2018 Phase 2 EUCTR2017-004302-18-SK Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
2018 Phase 2 EUCTR2017-004302-18-SE Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
2018 Phase 2 EUCTR2017-004302-18-FR Bulgaria;Croatia;Egypt;Finland;France;Lebanon;Oman;Romania;Slovakia;Sweden;Ukraine;
2018 Phase 2 EUCTR2017-004302-18-BG Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
G451990
GALAPAGOS NV
2018 Phase 3 EUCTR2018-001406-29-IT Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
2016 Phase 2 EUCTR2015-004157-41-IT Italy;United Kingdom;
Galapagos NV
2019 Phase 3 EUCTR2018-001406-29-NL Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
2019 Phase 3 EUCTR2018-001406-29-HU Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
2019 Phase 3 EUCTR2018-001406-29-FR Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
2019 Phase 3 EUCTR2018-001405-87-GR Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001405-87-GB Australia;Belgium;Brazil;Chile;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001405-87-DE Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001405-87-CZ Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001405-87-BE Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2018-001406-29-PL Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
2018 Phase 3 EUCTR2018-001405-87-ES Australia;Belgium;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2018-001405-87-DK Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004157-41-GB Ukraine;United Kingdom;
GB0139
Galecto Biotech AB
2019 Phase 2 NCT03832946 Australia;Belgium;Canada;France;Georgia;Germany;Ireland;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
GB0139 (previously known as TD139)
Galecto Biotech AB
2020 Phase 2 EUCTR2018-002664-73-IE Australia;Belgium;Canada;France;Georgia;Germany;Ireland;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002664-73-PL Australia;Belgium;Canada;France;Georgia;Germany;Ireland;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
GBT440
Global Blood Therapeutics
2016 Phase 2 NCT02989168 United Kingdom;United States;
2016 Phase 2 NCT02846324 United States;
GBT440 300 mg capsule
Global Blood Therapeutics Inc.
2017 Phase 2 EUCTR2017-001276-27-GB United Kingdom;United States;
GBT440 300 mg tablet
Global Blood Therapeutics Inc.
2017 Phase 2 EUCTR2017-001276-27-GB United Kingdom;United States;
GC1008
Genzyme, a Sanofi Company
2005 Phase 1 NCT00125385 Belgium;United States;
GKT137831
University of Alabama at Birmingham
2020 Phase 2 NCT03865927 United States;
GLPG1205
Galapagos NV
2019 Phase 2 EUCTR2017-004302-18-HR Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
2019 Phase 2 EUCTR2017-004302-18-FI Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
2018 Phase 2 NCT03725852 Bulgaria;Croatia;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
2018 Phase 2 EUCTR2017-004302-18-SK Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
2018 Phase 2 EUCTR2017-004302-18-SE Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
2018 Phase 2 EUCTR2017-004302-18-FR Bulgaria;Croatia;Egypt;Finland;France;Lebanon;Oman;Romania;Slovakia;Sweden;Ukraine;
2018 Phase 2 EUCTR2017-004302-18-BG Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
GLPG1690
GALAPAGOS NV
2018 Phase 3 EUCTR2018-001406-29-IT Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
2016 Phase 2 EUCTR2015-004157-41-IT Italy;United Kingdom;
Galapagos NV
2019 Phase 3 EUCTR2018-001406-29-NL Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
2019 Phase 3 EUCTR2018-001406-29-HU Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
2019 Phase 3 EUCTR2018-001406-29-FR Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
2019 Phase 3 EUCTR2018-001405-87-GR Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001405-87-GB Australia;Belgium;Brazil;Chile;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001405-87-DE Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001405-87-CZ Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001405-87-BE Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 NCT03733444 Argentina;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
2018 Phase 3 NCT03711162 Australia;Belgium;Brazil;Chile;Czechia;Denmark;Germany;Greece;Japan;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2018-001406-29-PL Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
2018 Phase 3 EUCTR2018-001405-87-ES Australia;Belgium;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2018-001405-87-DK Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004157-41-GB Ukraine;United Kingdom;
GLPG1690 600 mg QD
Galapagos NV
2016 Phase 2 NCT02738801 Italy;Ukraine;United Kingdom;
GS-6624
Gilead Sciences
2010 Phase 1 NCT01362231 United States;
Gilead Sciences, Inc.
2013 Phase 2 EUCTR2012-001571-36-GB Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2012-001571-36-CZ Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2012-001571-36-BE Australia;Belgium;Canada;Czech Republic;France;Germany;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Poland;Spain;Switzerland;United Kingdom;United States;
2013 - EUCTR2012-001571-36-PL Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2013 - EUCTR2012-001571-36-IT Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2013 - EUCTR2012-001571-36-ES Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2013 - EUCTR2012-001571-36-DE Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
GSK2126458
GlaxoSmithKline
2013 Phase 1 NCT01725139 United Kingdom;
GSK3008348
GlaxoSmithKline
2017 Phase 1 NCT03069989 United Kingdom;
GSK3008348 Nebuliser solution
GlaxoSmithKline
2015 Phase 1 NCT02612051 United Kingdom;
Gallium68-Dota-Noc
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
2012 - EUCTR2011-003687-78-IT Italy;
2009 - EUCTR2008-007168-40-IT Italy;
Gefapixant
Afferent Pharmaceuticals, Inc.
2015 Phase 2 NCT02502097 United States;
2015 Phase 2 NCT02477709 United States;
Granulocyte Colony Stimulating Factor
Shanghai Pulmonary Hospital
2015 - ChiCTR-OOC-15005862 China;
HEC 68498
Sunshine Lake Pharma Co., Ltd.
2018 Phase 1 NCT03502902 United States;
HEC585
Sunshine Lake Pharma Co., Ltd.
2020 Phase 1 NCT04512170 China;
2017 Phase 1 NCT03092102 United States;
HZN-825
Horizon Therapeutics Ireland DAC
2022 Phase 2 EUCTR2021-001253-32-GR Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Italy;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States;
2022 Phase 2 EUCTR2021-001253-32-ES Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Italy;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 2 NCT05032066 United States;
High dose BIBF 1120 twice daily
Boehringer Ingelheim
2007 Phase 2 NCT00514683 Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;El Salvador;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;South Africa;Spain;Taiwan;Turkey;United Kingdom;
Humanized anti-alpha v beta 6 mAb
BIOGEN IDEC RESEARCH LIMITED
2018 Phase 2 EUCTR2017-003158-18-IT Argentina;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
Biogen Idec Research Limited
2019 Phase 2 EUCTR2017-003158-18-PL Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2019 Phase 2 EUCTR2017-003158-18-DE Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003158-18-NL Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003158-18-GR Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003158-18-GB Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003158-18-ES Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003158-18-DK Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003158-18-CZ Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003158-18-BE Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
Hydroxyurea
Paul Szabolcs
2018 Phase 1/Phase 2 NCT03500731 United States;
Hyperoxia
University of British Columbia
2022 - NCT03800017 -
Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment
Duke University
2020 Phase 2 NCT04071769 United States;
Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment
Duke University
2022 Phase 2 NCT05241275 -
Hyperpolarized 129-Xenon gas
Bastiaan Driehuys
2015 Phase 1 NCT02478268 United States;
Hyperpolarized Xe129
University of Kansas Medical Center
2022 Phase 2 NCT04677426 -
IDL-2965 Oral Capsule
Indalo Therapeutics, Inc.
2019 Phase 1 NCT03949530 United Kingdom;
INO
Bellerophon Pulse Technologies LLC
2014 Phase 1;Phase 2 EUCTR2014-003423-21-BE Belgium;
INOmax 400ppm mol/mol inhalation gas
Bellerophon Pulse Technologies LLC
2014 Phase 1;Phase 2 EUCTR2014-003423-21-BE Belgium;
INS018_055
InSilico Medicine Hong Kong Limited
2022 Phase 1 NCT05154240 New Zealand;
IV Deployment Of cSVF In Sterile Normal Saline IV Solution
Black Tie Medical, Inc.
2020 Early Phase 1 NCT04326036 United States;
IW001
ImmuneWorks
2010 Phase 1 NCT01199887 United States;
Ifenprodil
Algernon Pharmaceuticals
2020 Phase 2 NCT04318704 Australia;New Zealand;
Iloprost Inhalation Solution (Ventavis)
Actelion
2005 Phase 2 NCT00109681 United States;
Imatinib Mesylate (Gleevec)
Daniels, Craig E., M.D.
2003 Phase 2/Phase 3 NCT00131274 -
Immukin
InterMune
2005 Phase 3 EUCTR2004-001261-17-IE Ireland;
2005 Phase 3 EUCTR2004-000029-31-IE Ireland;
Inhaled Nitric Oxide
Geno LLC
2011 Phase 2 NCT01265888 United States;
Inhaled Nitric Oxide - 30 mcg/kg IBW/hr
Bellerophon
2015 Phase 1 NCT02267655 Belgium;
Inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr
Bellerophon
2015 Phase 1 NCT02267655 Belgium;
Inhaled TD139
Galecto Biotech AB
2014 Phase 1/Phase 2 NCT02257177 United Kingdom;
Inhaled Treprostinil
United Therapeutics
2022 Phase 3 NCT05255991 -
2022 Phase 3 NCT04905693 -
2021 Phase 3 NCT04708782 United States;
Inhaled carbon monoxide
Brigham and Women's Hospital
2011 Phase 2 NCT01214187 United States;
Inhaled nitric oxide 75 mcg/kg IBW/hr
Bellerophon
2015 Phase 1 NCT02267655 Belgium;
Interferon alpha oral lozenge
Texas Tech University Health Sciences Center
2000 Phase 2 NCT01442779 United States;
Interferon gamma-1b
InterMune
2005 Phase 3 EUCTR2004-001261-17-IE Ireland;
2005 Phase 3 EUCTR2004-000029-31-IE Ireland;
2003 Phase 3 NCT00076635 United States;
Interferon gamma-1b (Actimmune)
InterMune
2003 Phase 3 NCT00075998 United States;
Interferon-alpha lozenges
Amarillo Biosciences, Inc.
2008 Phase 2 NCT00690885 United States;
Interferon-gamma 1b
InterMune
2002 Phase 3 NCT00052039 Italy;
2002 Phase 2 NCT00052052 United States;
2001 Phase 2 NCT00047658 United States;
2000 Phase 3 NCT00047645 United States;
Intermediate dose BIBF 1120 twice daily
Boehringer Ingelheim
2007 Phase 2 NCT00514683 Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;El Salvador;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;South Africa;Spain;Taiwan;Turkey;United Kingdom;
Jaktinib Dihydrochloride Monohydrate 50mg BID and Mimic tablets of jakitinib hydrochloride 75mg BID and Acetylcysteine Effervescent Tablets
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2020 Phase 2 NCT04312594 China;
Jaktinib Dihydrochloride Monohydrate 75mg BID and Mimic tablets of jakitinib hydrochloride 50mg BID and Acetylcysteine Effervescent Tablets
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2020 Phase 2 NCT04312594 China;
Jin-shui Huan-xian granule
Henan University of Traditional Chinese Medicine
2020 - NCT04187690 China;
KD025
Kadmon Corporation, LLC
2016 Phase 2 NCT02688647 United States;
L - Antineoplastic and immunomodulating agents
Boehringer Ingelheim
2017 - NCT03281200 Spain;
L01 - Antineoplastic agents
Boehringer Ingelheim
2017 - NCT03281200 Spain;
L01X - Other antineoplastic agents
Boehringer Ingelheim
2017 - NCT03281200 Spain;
L01XE - Protein kinase inhibitors
Boehringer Ingelheim
2017 - NCT03281200 Spain;
L01XE31 - Nintedanib
Boehringer Ingelheim
2017 - NCT03281200 Spain;
LANREOTIDE ACETATE
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
2012 - EUCTR2011-003687-78-IT Italy;
LPA1
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2020 Phase 2 EUCTR2019-003992-21-IT Argentina;Australia;Belgium;Brazil;Canada;Chile;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Spain;Taiwan;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2020 Phase 2 EUCTR2019-003992-21-DE Argentina;Australia;Belgium;Brazil;Canada;Chile;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003992-21-BE Argentina;Australia;Belgium;Brazil;Canada;Chile;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Lansoprazole
Huang Jinhong
2021 Phase 1 JPRN-jRCT2071210016 Japan;
Norfolk and Norwich University Hospitals NHS Foundation Trust
2021 Phase 3 NCT04965298 United Kingdom;
2020 Phase 3 EUCTR2020-000041-14-GB United Kingdom;
Lebrikizumab
Chugai Pharmaceutical Co., Ltd.
2014 Phase 2 JPRN-JapicCTI-142708 -
Hoffmann-La Roche
2013 Phase 2 NCT01872689 Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
Letairis
Gilead Sciences Incorporated
2010 - EUCTR2008-004405-34-CZ Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-004405-34-FR Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2009-011169-98-IT Austria;Czech Republic;Germany;Italy;United Kingdom;
2009 - EUCTR2008-004405-34-NL Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-004405-34-IE Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-004405-34-GB Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-004405-34-ES Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-004405-34-BE Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-004405-34-AT Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
- - EUCTR2008-004405-34-DE Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
Gilead Sciences, Inc
2009 - EUCTR2009-011169-98-GB Austria;Czech Republic;Germany;Italy;United Kingdom;
2009 - EUCTR2009-011169-98-DE Austria;Czech Republic;Germany;Italy;United Kingdom;
2009 - EUCTR2009-011169-98-AT Austria;Czech Republic;Germany;Italy;United Kingdom;
Gilead Sciences, Inc.
2011 - EUCTR2009-011169-98-CZ Austria;Czech Republic;Germany;Italy;United Kingdom;
Letermovir
Fernanda P Silveira, MD, MS
2021 Phase 2 NCT05041426 United States;
Liberase Enzyme (Roche)
Black Tie Medical, Inc.
2020 Early Phase 1 NCT04326036 United States;
Losartan
University of South Florida
2009 - NCT00879879 United States;
Low dose BIBF 1120 twice daily
Boehringer Ingelheim
2007 Phase 2 NCT00514683 Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;El Salvador;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;South Africa;Spain;Taiwan;Turkey;United Kingdom;
Low dose BIBF1120 once daily
Boehringer Ingelheim
2007 Phase 2 NCT00514683 Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;El Salvador;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;South Africa;Spain;Taiwan;Turkey;United Kingdom;
Lung Spheroid Stem Cells 100 million
University of North Carolina, Chapel Hill
2020 Phase 1 NCT04262167 United States;
Lung Spheroid Stem Cells 200 million
University of North Carolina, Chapel Hill
2020 Phase 1 NCT04262167 United States;
Lung stem cells
Shanghai East Hospital
2016 Phase 1/Phase 2 NCT02745184 China;
MG-S-2525
Metagone Biotech Inc.
2019 Phase 1 NCT03650075 Taiwan;
MRI
Bastiaan Driehuys
2015 Phase 1 NCT02478268 United States;
Macitentan
ACTELION Pharmaceuticals Ltd.
2011 - EUCTR2010-024211-13-SI Australia;Canada;Germany;Israel;Slovenia;South Africa;Spain;Sweden;Turkey;United States;
2011 - EUCTR2010-024211-13-SE Australia;Canada;Germany;Israel;South Africa;Spain;Sweden;Turkey;United States;
2011 - EUCTR2010-024211-13-ES Australia;Canada;Germany;Israel;South Africa;Spain;Sweden;Turkey;United States;
2011 - EUCTR2010-024211-13-DE Australia;Canada;Germany;Israel;South Africa;Spain;Sweden;Turkey;United States;
Actelion
2011 Phase 2 NCT01346930 -
Actelion Pharamceuticals Ltd
2010 - EUCTR2008-006054-17-IT France;Germany;Italy;Slovenia;Spain;Sweden;
Actelion Pharmaceuticals Ltd.
2009 Phase 2 EUCTR2008-006054-17-ES France;Germany;Italy;Slovenia;Spain;Sweden;
2009 - EUCTR2008-006054-17-SI France;Germany;Italy;Slovenia;Spain;Sweden;
2009 - EUCTR2008-006054-17-SE France;Germany;Italy;Slovenia;Spain;Sweden;
- - EUCTR2008-006054-17-DE France;Germany;Italy;Slovenia;Spain;Sweden;
Medical air
Queen's University
2021 Early Phase 1 NCT05052229 Canada;
Schön Klinik Berchtesgadener Land
2016 - NCT03050255 Germany;
Medical air (sham O2)
George Papanicolaou Hospital
2018 - NCT03688334 Greece;
Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)
Black Tie Medical, Inc.
2020 Early Phase 1 NCT04326036 United States;
Minocycline
University of California, Los Angeles
2006 Phase 3 NCT00203697 United States;
Montelukast
Maisonneuve-Rosemont Hospital
2011 Phase 2 NCT01432080 Canada;
Shanghai Pulmonary Hospital
2015 - ChiCTR-OOC-15005841 -
Morphine Sulfate
Royal Brompton & Harefield NHS Foundation Trust
2020 Phase 3 NCT04429516 United Kingdom;
Morphine hydrochloride
Medical University of Gdansk
2020 Phase 3 NCT04497831 -
Moxifloxacin
Respiratory Department, Peking Union Medical College Hospital
2011 - ChiCTR-TRC-12002372 China;
Mycophenolate mofetil
Peking Union Medical College Hospital
2019 Phase 4 ChiCTR1900027121 China;
N-Acetylcysteine, (NAC)
InterMune International AG.
2013 Phase 2 EUCTR2012-000564-14-GB Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
2013 - EUCTR2012-000564-14-SE Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
2013 - EUCTR2012-000564-14-IT Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
2013 - EUCTR2012-000564-14-DK Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
2013 - EUCTR2012-000564-14-DE Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
2013 - EUCTR2012-000564-14-BE Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
2013 - EUCTR2012-000564-14-AT Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
N-acetyl cysteine
University of Colorado, Denver
2022 Phase 1/Phase 2 NCT03720483 United States;
Weill Medical College of Cornell University
2020 Phase 3 NCT04300920 United States;
N-acetylcysteine
Hoffmann-La Roche
2013 Phase 2 NCT02707640 Austria;Belgium;Denmark;France;Germany;Italy;Sweden;United Kingdom;
Zambon SpA
2000 Phase 3 NCT00639496 Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
NAC
Department of Respiratory Medicine, Toho University Omori Medical Center, Tokyo
2009 - JPRN-UMIN000016045 Japan;
Grant for Research on Diffuse Lung Disease from the Ministry of Health, Labour and Welfare of Japan.
2015 - JPRN-UMIN000015508 Japan;
Shanghai Pulmonary Hospital, Tongji University School of Medicine
2020 - ChiCTR2000031386 China;
Toho University Omori Medical CenterDepartment of Respiratory Medicine
2009 - JPRN-UMIN000007663 Japan;
NALBUPHINE HYDROCHLORIDE
Trevi Therapeutics, Inc.
2019 Phase 2 EUCTR2018-004744-31-GB United Kingdom;
ND-L02-s0201
Nitto Denko Corporation
2018 Phase 2 NCT03538301 Germany;Japan;United Kingdom;United States;
ND-L02-s0201 for injection
Nitto Denko Corporation
2018 Phase 2 EUCTR2017-004919-39-DE Germany;Japan;United Kingdom;United States;
NIP292 tablet
The National Institutes of Pharmaceutical R&D Co. Ltd, China
2019 Phase 1 NCT04720443 United States;
NIP292 tablets
The National Institutes of Pharmaceutical R&D Co. Ltd, China
2019 Phase 1 NCT04720443 United States;
Nalbuphine ER
Trevi Therapeutics
2019 Phase 2 NCT04030026 United Kingdom;
Nalbuphine Extended-Realease (ER) Tablets
Trevi Therapeutics, Inc.
2019 Phase 2 EUCTR2018-004744-31-GB United Kingdom;
Nalbuphine Extended-Release (ER) Tablets
Trevi Therapeutics, Inc.
2019 Phase 2 EUCTR2018-004744-31-GB United Kingdom;
Nebivolol
Daewoong Pharmaceutical Co. LTD.
2021 Phase 1 NCT04888728 Korea, Republic of;
Nintedanib
BOEHRINGER ING.
2012 Phase 3 EUCTR2011-002766-21-IT Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
BOEHRINGER-INGELHEIM ITALIA S.P.A.
2016 Phase 3 EUCTR2015-002619-14-IT Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Boehringer Ingelheim
2021 - NCT05022784 United States;
2021 - NCT04739150 Belgium;
2021 - NCT04525547 Korea, Republic of;
2019 - NCT03958071 United States;
2019 - NCT03710824 Greece;
2018 Phase 4 NCT03717012 United States;
2016 Phase 4 NCT02788474 Australia;Belgium;Czech Republic;Czechia;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2016 Phase 4 NCT02606877 United Kingdom;
2016 Phase 3 NCT02802345 Australia;Belgium;Canada;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
2015 Phase 4 NCT02579603 Canada;France;Germany;Italy;Netherlands;United States;
2015 - NCT02607722 Japan;
2014 - NCT02230982 Brazil;
2014 - NCT02171156 United States;
2013 Phase 3 NCT01979952 Canada;Turkey;United States;
2012 Phase 3 EUCTR2011-002766-21-FI Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
2011 Phase 2 NCT01417156 Japan;
Boehringer Ingelheim Hellas
2012 Phase 3 EUCTR2011-002766-21-GR Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
Boehringer Ingelheim España S.A
2012 Phase 3 EUCTR2011-002766-21-ES Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
Boehringer Ingelheim Limited
2013 Phase 3 EUCTR2011-002766-21-IE Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
2012 Phase 3 EUCTR2011-002766-21-GB Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co. KG
2012 Phase 3 EUCTR2011-002766-21-DE Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
Boehringer Ingelheim RCV GmBH & Co KG
2010 Phase 2 EUCTR2009-013788-21-HU Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim RCV GmbH & Co KG
2012 Phase 3 EUCTR2011-002766-21-CZ Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
2010 Phase 2 EUCTR2009-013788-21-CZ Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Russian Federation;Spain;United Kingdom;
Central Japan Lung Study Grou
2017 Phase 4 JPRN-UMIN000026376 Japan;
Daewoong Pharmaceutical Co. LTD.
2021 Phase 1 NCT04888715 Korea, Republic of;
Hirosaki University Graduate School of Medicine
2016 - JPRN-UMIN000021591 Japan;
Hoffmann-La Roche
2016 Phase 4 NCT02598193 Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
IKEDA Satoshi
2019 Phase 2 JPRN-jRCTs031190119 Japan;
Intellectual Disabilities
Kanagawa Cardiovascular and Respiratory Center
2016 - JPRN-UMIN000020722 Japan;
2015 Phase 2 JPRN-UMIN000019436 Japan;
Kayamori Takefumi
2021 Phase 3 JPRN-jRCT2031210008 Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Germany;Greece;Japan;Peru;Spain;Taiwan;Turkey;USA;United Kingdom;
National Hospital Organization Ibarakihigashi National HospitalThe center of Chest Diseases and Severe Motor&
Okamoto Isamu
2017 Phase 3 JPRN-jRCTs071180049 Japan;
Research Institute for Diseases of the Chest, Kyushu University
2017 Phase 3 JPRN-UMIN000026799 Japan;
SCS Boehringer Ingelheim Ingelheim Comm.V
2012 Phase 3 EUCTR2011-002766-21-BE Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
Temple University
2019 Phase 2 NCT03562416 United States;
Unilfarma - União Internacional de Lab. Farmacêuticos, Lda
2012 Phase 3 EUCTR2011-002766-21-PT Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
Nitric Oxide
Queen's University
2021 Early Phase 1 NCT05052229 Canada;
Nivolumab
Kobe city medical center general hospital
2016 - JPRN-UMIN000022037 Japan;
None
Blade Therapeutics, Inc.
2020 Phase 2 EUCTR2019-004998-34-GB United Kingdom;
Norfolk and Norwich University Hospital NHS Foundation Trust
2014 Phase 3 EUCTR2014-004058-32-GB United Kingdom;
OFEV®
Boehringer Ingelheim
2020 - NCT04614441 Taiwan;
ORIN1001
Orinove, Inc.
2021 Phase 1 NCT04643769 United States;
Octreotide
Institut National de la Santé Et de la Recherche Médicale, France
2006 Phase 1/Phase 2 NCT00463983 France;
Ofev
BOEHRINGER-INGELHEIM ITALIA S.P.A.
2015 Phase 4 EUCTR2015-000640-42-IT Canada;France;Germany;Italy;Netherlands;United States;
F. HOFFMANN - LA ROCHE LTD.
2015 Phase 4 EUCTR2015-003280-11-IT Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
F. Hoffmann-La Roche Ltd
2016 Phase 4 EUCTR2015-003280-11-NL Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
2016 Phase 4 EUCTR2015-003280-11-DK Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
2016 Phase 4 EUCTR2015-003280-11-DE Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
Roche Farma S.A., que representa en España a F. Hoffmann-La Roche Ltd
2015 Phase 4 EUCTR2015-003280-11-ES Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
Ofev 100 mg capsule
BOEHRINGER-INGELHEIM ITALIA S.P.A.
2016 Phase 3 EUCTR2015-002619-14-IT Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Boehringer Ingelheim España, S.A.
2016 Phase 4 EUCTR2015-003148-38-ES Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-002619-14-ES Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Boehringer Ingelheim Finland Ky
2016 Phase 4 EUCTR2015-003148-38-FI Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
Boehringer Ingelheim France
2017 Phase 3 EUCTR2015-002619-14-FR Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
2016 Phase 4 EUCTR2015-003148-38-FR Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2015 Phase 4 EUCTR2015-000640-42-FR Canada;France;Germany;Italy;Netherlands;United States;
Boehringer Ingelheim Limited
2016 Phase 4 EUCTR2015-003148-38-GB Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-002619-14-GB Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co. KG
2016 Phase 4 EUCTR2015-003148-38-DE Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-002619-14-DE Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co.KG
2015 Phase 4 EUCTR2015-000640-42-DE Canada;France;Germany;Italy;Netherlands;United States;
Boehringer Ingelheim RCV GmbH & Co KG
2016 Phase 4 EUCTR2015-003148-38-PL Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2016 Phase 4 EUCTR2015-003148-38-HU Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2016 Phase 4 EUCTR2015-003148-38-CZ Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
Boehringer Ingelheim bv
2015 Phase 4 EUCTR2015-000640-42-NL Canada;France;Germany;Italy;Netherlands;United States;
SCS Boehringer Ingelheim Comm. V
2016 Phase 3 EUCTR2015-002619-14-BE Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
SCS Boehringer Ingelheim Comm. V
2016 Phase 4 EUCTR2015-003148-38-BE Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
Ofev 150 mg capsule
BOEHRINGER-INGELHEIM ITALIA S.P.A.
2016 Phase 3 EUCTR2015-002619-14-IT Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Boehringer Ingelheim España, S.A.
2016 Phase 4 EUCTR2015-003148-38-ES Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-002619-14-ES Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Boehringer Ingelheim Finland Ky
2016 Phase 4 EUCTR2015-003148-38-FI Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
Boehringer Ingelheim France
2017 Phase 3 EUCTR2015-002619-14-FR Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
2016 Phase 4 EUCTR2015-003148-38-FR Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2015 Phase 4 EUCTR2015-000640-42-FR Canada;France;Germany;Italy;Netherlands;United States;
Boehringer Ingelheim Limited
2016 Phase 4 EUCTR2015-003148-38-GB Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-002619-14-GB Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co. KG
2016 Phase 4 EUCTR2015-003148-38-DE Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-002619-14-DE Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co.KG
2015 Phase 4 EUCTR2015-000640-42-DE Canada;France;Germany;Italy;Netherlands;United States;
Boehringer Ingelheim RCV GmbH & Co KG
2016 Phase 4 EUCTR2015-003148-38-PL Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2016 Phase 4 EUCTR2015-003148-38-HU Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2016 Phase 4 EUCTR2015-003148-38-CZ Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
Boehringer Ingelheim bv
2015 Phase 4 EUCTR2015-000640-42-NL Canada;France;Germany;Italy;Netherlands;United States;
SCS Boehringer Ingelheim Comm. V
2016 Phase 3 EUCTR2015-002619-14-BE Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
SCS Boehringer Ingelheim Comm. V
2016 Phase 4 EUCTR2015-003148-38-BE Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
Omeprazole
Newcastle-upon-Tyne Hospitals NHS Trust
2014 Phase 2 NCT02085018 United Kingdom;
Omeprazole (UK licensed generic product)
Newcastle Upon Tyne Hospitals NHS Foundation Trust
2013 Phase 2 EUCTR2013-003301-26-GB United Kingdom;
Oxygen
Brigham and Women's Hospital
2011 Phase 2 NCT01214187 United States;
Department of Respiratory Medicine and Allergology, Kinki University School of Medicine
2011 - JPRN-UMIN000005098 Japan;
George Papanicolaou Hospital
2018 - NCT03688334 Greece;
Parc de Salut Mar
2019 - NCT04564664 Spain;
Schön Klinik Berchtesgadener Land
2016 - NCT03050255 Germany;
Tosei General Hospital
2009 - JPRN-UMIN000025256 Japan;
University of British Columbia
2015 - NCT02551068 Canada;
Oxymizer® compared to CNC
Klinikum Berchtesgadener Land der Schön-Kliniken
2014 - NCT02268981 Germany;
PA101
Patara Pharma
2015 Phase 2 NCT02412020 Netherlands;United Kingdom;
2015 - EUCTR2014-004025-40-NL Netherlands;United Kingdom;
2014 Phase 2 EUCTR2014-004025-40-GB Netherlands;United Kingdom;
PBI4050
Liminal BioSciences Ltd.
2015 Phase 2 NCT02538536 Canada;
PD00377 Na-salt
Vicore Pharma AB
2018 Phase 2 EUCTR2017-004923-63-GB Bulgaria;Poland;Serbia;United Kingdom;
PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714
University of Alabama at Birmingham
2020 Phase 1 NCT04362644 United States;
PIR, S-7701
INTERMUNE
2006 - EUCTR2006-000252-41-IT Italy;United Kingdom;
InterMune, Inc.
2008 Phase 3 EUCTR2007-007800-13-IE Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-007800-13-GB Australia;Belgium;Canada;France;Germany;Ireland;Italy;Poland;Spain;United Kingdom;United States;
2008 Phase 3 EUCTR2007-007800-13-ES Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-007800-13-DE Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2008 - EUCTR2007-007800-13-BE Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
PLN-74809
Pliant Therapeutics, Inc.
2020 Phase 2 NCT04396756 Australia;Belgium;Canada;Italy;Netherlands;New Zealand;United States;
2019 Phase 2 NCT04072315 United States;
PLN-74809-000
Pliant Therapeutics Inc.
2020 Phase 2 EUCTR2019-002709-23-IT Australia;Belgium;Canada;France;Germany;Italy;Netherlands;New Zealand;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002709-23-GB Australia;Belgium;Canada;France;Germany;Italy;Netherlands;New Zealand;United Kingdom;United States;
PLN-74809-020
Pliant Therapeutics Inc.
2021 Phase 2 EUCTR2019-002709-23-NL Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002709-23-DE Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;United Kingdom;United States;
PMG1015 Dose 1
Pulmongene Ltd.
2021 Phase 1 NCT05022771 Australia;
PMG1015 Dose 2
Pulmongene Ltd.
2021 Phase 1 NCT05022771 Australia;
PMG1015 Dose 3
Pulmongene Ltd.
2021 Phase 1 NCT05022771 Australia;
PMG1015 Dose 4
Pulmongene Ltd.
2021 Phase 1 NCT05022771 Australia;
PMG1015 Dose 5
Pulmongene Ltd.
2021 Phase 1 NCT05022771 Australia;
PMG1015 Dose 6
Pulmongene Ltd.
2021 Phase 1 NCT05022771 Australia;
PRIVIGEN 100mg/ml
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2018 Phase 3 EUCTR2018-002632-24-FR France;
PRM-151
Hoffmann-La Roche
2021 Phase 3 NCT04594707 Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Puerto Rico;South Africa;Spain;Sweden;Switzerland;Ukraine;United States;
2021 Phase 3 NCT04552899 Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Puerto Rico;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2015 Phase 2 NCT02550873 Belgium;Czech Republic;Czechia;Germany;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
2011 Phase 1 NCT01254409 Netherlands;United States;
Makino Ryoko
2021 Phase 3 JPRN-jRCT2051210129 Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;South Korea;Spain;Sweden;
PROMEDIOR, INC.
2015 Phase 2 EUCTR2014-004782-24-IT Belgium;Czech Republic;Czechia;France;Germany;Hungary;Italy;Netherlands;Spain;United Kingdom;United States;
Promedior inc
2015 - EUCTR2014-004782-24-NL Netherlands;
Promedior, Inc.
2016 Phase 2 EUCTR2014-004782-24-HU Belgium;Czech Republic;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
2016 Phase 2 EUCTR2014-004782-24-ES Belgium;Czech Republic;Germany;Hungary;Netherlands;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2014-004782-24-DE Belgium;Czech Republic;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
2016 Phase 2 EUCTR2014-004782-24-CZ Belgium;Czech Republic;France;Germany;Hungary;Netherlands;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2014-004782-24-BE Belgium;Czech Republic;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
Shimoda Yukiko
2022 Phase 3 JPRN-jRCT2001210001 Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;South Korea;Spain;Sweden;
PZN 8881655(RochePharma AG)
Justus Liebig Universität Giessen
2015 Phase 2 EUCTR2014-000861-32-DE Germany;
Paclitaxel
Hirosaki University Graduate School of Medicine
2016 - JPRN-UMIN000021591 Japan;
IP lung cancer study group
2012 - JPRN-UMIN000018322 Japan;
2012 - JPRN-UMIN000018248 Japan;
Katakami Nobuyuki
2013 Phase 2 JPRN-jRCTs061180046 Japan;
2013 Phase 2 JPRN-jRCTs051180149 Japan;
Lung Oncology Group in Kyushu, Japan (LOGIK)
2007 - JPRN-UMIN000015929 Japan;
Okamoto Isamu
2017 Phase 3 JPRN-jRCTs071180049 Japan;
Research Institute for Diseases of the Chest, Kyushu University
2017 Phase 3 JPRN-UMIN000026799 Japan;
Pamrevlumab
FibroGen
2020 Phase 3 NCT04419558 Brazil;Colombia;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;Ireland;Italy;Korea, Republic of;Lebanon;Mexico;Netherlands;Peru;Poland;Serbia;Spain;Switzerland;Ukraine;United Kingdom;United States;
2019 Phase 3 NCT03955146 Argentina;Australia;Chile;China;Czechia;France;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Lebanon;Netherlands;Peru;Russian Federation;Spain;Taiwan;United States;
2013 Phase 2 NCT01890265 Australia;Bulgaria;Canada;India;New Zealand;South Africa;United States;
FibroGen, Inc.
2016 Phase 2 EUCTR2014-005658-20-BG Australia;Bulgaria;Canada;India;New Zealand;South Africa;United States;
Tracy Ganske
2022 Phase 3 JPRN-jRCT2051210169 Argentina;Australia;Chile;Hong Kong;Japan;Russia;South Korea;Taiwan;United States;the People's Republic of China;
Paroxetine
Daewoong Pharmaceutical Co. LTD.
2021 Phase 1 NCT04888728 Korea, Republic of;
Pirfenidone
Beijing Kawin Technology Share-Holding Co., Ltd.
2012 Phase 2 NCT01504334 China;
Boehringer Ingelheim
2019 - NCT03958071 United States;
2016 Phase 4 NCT02606877 United Kingdom;
2015 Phase 4 NCT02579603 Canada;France;Germany;Italy;Netherlands;United States;
Bristol-Myers Squibb
2019 Phase 1 NCT03981094 United States;
Daewoong Pharmaceutical Co. LTD.
2021 Phase 1 NCT04888715 Korea, Republic of;
Department of Respiratory Medicine and Allergology, Kinki University Faculty of Medicine
2012 - JPRN-UMIN000008541 Japan;
Department of Respiratory Medicine, Toho University Omori Medical Center, Tokyo
2009 - JPRN-UMIN000016045 Japan;
Genentech, Inc.
2014 - NCT02141087 -
2011 Phase 3 NCT01366209 United States;
2008 Phase 3 NCT00662038 United States;
2006 Phase 3 NCT00287729 United States;
2006 Phase 3 NCT00287716 United States;
2003 Phase 2 NCT00080223 United States;
Grant for Research on Diffuse Lung Disease from the Ministry of Health, Labour and Welfare of Japan.
2015 - JPRN-UMIN000015508 Japan;
Hoffmann-La Roche
2017 Phase 3 NCT03208933 Russian Federation;
2017 - NCT03115619 Greece;
2016 Phase 4 NCT02598193 Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
2016 Phase 2 NCT02951429 Belgium;Canada;Czech Republic;Czechia;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 1 NCT02648048 Germany;United States;
2014 - NCT02622477 Germany;
2013 Phase 2 NCT02707640 Austria;Belgium;Denmark;France;Germany;Italy;Sweden;United Kingdom;
2013 Phase 2 NCT01872689 Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
2012 - NCT02699879 Austria;Denmark;Finland;France;Germany;Ireland;Italy;Norway;Sweden;United Kingdom;
INTERMUNE
2008 - EUCTR2007-007800-13-IT Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
Intellectual Disabilities
InterMune, Inc.
2008 Phase 3 EUCTR2007-007800-13-IE Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-007800-13-GB Australia;Belgium;Canada;France;Germany;Ireland;Italy;Poland;Spain;United Kingdom;United States;
2008 Phase 3 EUCTR2007-007800-13-ES Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-007800-13-DE Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2008 - EUCTR2007-007800-13-FR Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2008 - EUCTR2007-007800-13-BE Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2006 Phase 3 EUCTR2006-000252-41-GB Italy;United Kingdom;
2006 Phase 3 EUCTR2006-000138-11-ES Belgium;Czech Republic;Germany;Ireland;Spain;
2006 - EUCTR2006-000138-11-DE Belgium;Czech Republic;Germany;Ireland;Spain;
2006 - EUCTR2006-000138-11-CZ Belgium;Czech Republic;Germany;Ireland;Spain;
2006 - EUCTR2006-000138-11-BE Belgium;Czech Republic;Germany;Ireland;Spain;
Kanagawa Cardiovascular and Respiratory Center
2015 Phase 2 JPRN-UMIN000019436 Japan;
Kayamori Takefumi
2021 Phase 3 JPRN-jRCT2031210008 Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Germany;Greece;Japan;Peru;Spain;Taiwan;Turkey;USA;United Kingdom;
National Hospital Organization Ibarakihigashi National Hospital
2015 - JPRN-UMIN000016826 Japan;
National Hospital Organization Ibarakihigashi National HospitalThe center of Chest Diseases and Severe Motor&
North East Japan Study Group
2017 Phase 3 JPRN-UMIN000029411 Japan;
Saitama Medical University
2009 - JPRN-UMIN000005793 Japan;
Shanghai Pulmonary Hospital, Shanghai, China
2011 Phase 2 NCT02136992 -
Tianjin Medical University General Hospital
2020 Phase 4 ChiCTR2000037602 China;
West Japan Oncology Group
2012 Phase 2 JPRN-UMIN000007774 Japan;
Pirfenidone Solution for Inhalation
Avalyn Pharma, Inc.
2021 Phase 2 EUCTR2020-005103-39-PL Australia;Czech Republic;Czechia;Netherlands;New Zealand;Poland;United Kingdom;
2021 Phase 2 EUCTR2020-005103-39-CZ Australia;Czech Republic;Czechia;Netherlands;New Zealand;Poland;United Kingdom;
Pirfenidone and nintedanib
Hospices Civils de Lyon
2020 Phase 4 NCT03939520 France;
Pirfenidone or nintedanib
Hospices Civils de Lyon
2020 Phase 4 NCT03939520 France;
Pirfenidoneone
Boehringer Ingelheim
2011 Phase 2 NCT01417156 Japan;
Placebo
ASAHI KASEI PHARMA CORPORATION
2016 Phase 3 JPRN-JapicCTI-163326 -
Chugai Pharmaceutical Co., Ltd.
2014 Phase 2 JPRN-JapicCTI-142708 -
Pomalidomide (CC-4047
Stanford University
2010 Phase 2 NCT01135199 United States;
Prednisone
Hospital Universitari Vall d'Hebron Research Institute
2020 Phase 4 NCT04534478 -
Maisonneuve-Rosemont Hospital
2011 Phase 2 NCT01432080 Canada;
QAX576
Novartis Pharma Services AG
2011 - EUCTR2010-020688-18-GB United Kingdom;
Novartis Pharmaceuticals
2010 Phase 2 NCT01266135 United Kingdom;United States;
2007 Phase 2 NCT00532233 United States;
RO0220912
F. HOFFMANN - LA ROCHE LTD.
2016 Phase 2 EUCTR2015-005131-40-IT Belgium;Canada;Czech Republic;Czechia;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2015 Phase 4 EUCTR2015-003280-11-IT Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
F. Hoffmann-La Roche Ltd
2017 Phase 2 EUCTR2015-005131-40-HU Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2017 Phase 2 EUCTR2015-005131-40-CZ Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 4 EUCTR2015-003280-11-NL Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
2016 Phase 4 EUCTR2015-003280-11-DK Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
2016 Phase 4 EUCTR2015-003280-11-DE Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
2016 Phase 2 EUCTR2015-005131-40-NL Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 2 EUCTR2015-005131-40-GR Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 2 EUCTR2015-005131-40-ES Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 2 EUCTR2015-005131-40-DE Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 2 EUCTR2015-005131-40-BE Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
Roche Farma S.A., que representa en España a F. Hoffmann-La Roche Ltd
2015 Phase 4 EUCTR2015-003280-11-ES Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
RO0280296
F. Hoffmann-La Roche Ltd
2017 Phase 2 EUCTR2015-005131-40-HU Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2017 Phase 2 EUCTR2015-005131-40-CZ Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 2 EUCTR2015-005131-40-NL Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 2 EUCTR2015-005131-40-GR Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 2 EUCTR2015-005131-40-ES Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 2 EUCTR2015-005131-40-DE Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 2 EUCTR2015-005131-40-BE Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
RO5490255
Chugai Pharmaceutical Co., Ltd.
2014 Phase 2 JPRN-JapicCTI-142708 -
RO5490255/F01-02
F. Hoffmann-La Roche Ltd
2014 Phase 2 EUCTR2013-001163-24-BE Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2013-001163-24-PL Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2013-001163-24-IT Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2013-001163-24-GB Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2013-001163-24-FR Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2013-001163-24-ES Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2013-001163-24-DE Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
RO7490677
F. HOFFMANN - LA ROCHE LTD.
2020 Phase 3 EUCTR2020-001429-30-IT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-000791-38-IT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
F. Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-001429-30-PT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-NO Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-NL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-HU Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-GR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-FR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-FI Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-DK Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-CZ Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-AT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-SE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-PT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-PL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-NO Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-NL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-HU Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-GR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-FI Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-DK Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-CZ Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
RO7490677/ F01-02
F. Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-001429-30-PL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
RO7490677/F01-01
F. Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-001429-30-SE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
RO7490677/F01-02
F. Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-001429-30-SE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
RO7490677/F01-03
F. Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-001429-30-SE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-PL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
RVT-1601
Respivant Sciences GmbH
2019 Phase 2 NCT03864328 Australia;Belgium;Canada;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
RVT-1601 (formerly, PA101B)
Respivant Sciences GmbH
2019 Phase 2 EUCTR2018-004447-23-NL Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004447-23-GB Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004447-23-DE Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;Turkey;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004447-23-CZ Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004447-23-BE Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
RVT-1601 (in precedenza PA101B)
Respivant Sciences, GmbH
2019 Phase 2 EUCTR2018-004447-23-IT Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
RXC007
Redx Pharma Plc
2021 Phase 1 NCT04931147 United Kingdom;
Recombinant human Pentraxin-2 (PRM-151)
F. HOFFMANN - LA ROCHE LTD.
2020 Phase 3 EUCTR2020-001429-30-IT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-000791-38-IT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
F. Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-001429-30-SE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-PT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-PL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-NO Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-NL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-HU Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-GR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-FR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-FI Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-DK Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-CZ Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-AT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-SE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-PT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-PL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-NO Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-NL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-HU Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-GR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-FI Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-DK Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-CZ Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Remicade
Academic Medical Centre
2007 - EUCTR2004-001876-37-DE Germany;
Revatio
BOEHRINGER-INGELHEIM ITALIA S.P.A.
2016 Phase 3 EUCTR2015-002619-14-IT Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Boehringer Ingelheim España, S.A.
2016 Phase 3 EUCTR2015-002619-14-ES Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Boehringer Ingelheim France
2017 Phase 3 EUCTR2015-002619-14-FR Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Boehringer Ingelheim Limited
2016 Phase 3 EUCTR2015-002619-14-GB Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co. KG
2016 Phase 3 EUCTR2015-002619-14-DE Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
SCS Boehringer Ingelheim Comm. V
2016 Phase 3 EUCTR2015-002619-14-BE Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Rituximab
Paul Szabolcs
2018 Phase 1/Phase 2 NCT03500731 United States;
University of Alabama at Birmingham
2014 Phase 2 NCT01969409 United States;
Ro 47-0203
ACTELION PHARMACEUTICALS LTD
2007 Phase 3 EUCTR2006-001183-24-SK Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-001183-24-GB Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-001183-24-ES Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2007 - EUCTR2006-001183-24-NL Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-001183-24-IE Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-001183-24-DK Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-001183-24-DE Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-001183-24-CZ Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-001183-24-AT Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2006 - EUCTR2006-001183-24-BE Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
Actelion Pharmaceuticals Ltd
2009 - EUCTR2007-001741-18-AT Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-001741-18-GB Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-001741-18-FR Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-001741-18-NL Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-001741-18-IE Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-001741-18-ES Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-001741-18-DE Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-001741-18-CZ Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-001741-18-BE Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
Routine steroid administration group
Yonsei University
2021 - NCT04996303 Korea, Republic of;
SAR100842
Horizon Therapeutics Ireland DAC
2022 Phase 2 EUCTR2021-001253-32-GR Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Italy;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States;
2022 Phase 2 EUCTR2021-001253-32-ES Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Italy;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States;
SAR156597
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
2015 Phase 2 EUCTR2014-003933-24-IT Czech Republic;Denmark;France;Germany;Greece;Italy;Portugal;Spain;United Kingdom;
Sanofi
2015 Phase 2 NCT02345070 Argentina;Australia;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States;
2012 Phase 1/Phase 2 NCT01529853 Belgium;Canada;Chile;Mexico;Spain;United States;
sanofi-aventis recherche & développement
2016 Phase 2 EUCTR2014-003933-24-PT Argentina;Australia;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003933-24-GR Argentina;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003933-24-GB Argentina;Australia;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003933-24-FR Argentina;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003933-24-ES Argentina;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003933-24-DK Argentina;Australia;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003933-24-DE Argentina;Australia;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003933-24-CZ Argentina;Australia;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States;
SEPTRIN
Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI)
2013 Phase 3 EUCTR2012-005409-38-ES Spain;
SHR-1906
Guangdong Hengrui Pharmaceutical Co., Ltd
2021 Phase 1 NCT04986540 -
SM04646
Samumed LLC
1900 Phase 2 NCT03591926 Australia;New Zealand;
SODIUM CROMOGLICATE
Respivant Sciences GmbH
2019 Phase 2 EUCTR2018-004447-23-NL Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004447-23-GB Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004447-23-DE Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;Turkey;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004447-23-CZ Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004447-23-BE Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
Respivant Sciences, GmbH
2019 Phase 2 EUCTR2018-004447-23-IT Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
Salbutamol
Royal Brompton & Harefield NHS Foundation Trust
2012 Phase 1 NCT01457261 United Kingdom;
Saracatinab
National Jewish Health
2020 Phase 1/Phase 2 NCT04598919 United States;
Septrin
University of East Anglia
2007 - EUCTR2007-002324-15-GB United Kingdom;
Sildenafil
Boehringer Ingelheim
2016 Phase 3 NCT02802345 Australia;Belgium;Canada;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
F. HOFFMANN - LA ROCHE LTD.
2016 Phase 2 EUCTR2015-005131-40-IT Belgium;Canada;Czech Republic;Czechia;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
Hoffmann-La Roche
2016 Phase 2 NCT02951429 Belgium;Canada;Czech Republic;Czechia;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
Rabin Medical Center
2011 Phase 4 NCT01382368 Israel;
University of California, Los Angeles
2007 Phase 4 NCT00625079 United States;
VA Office of Research and Development
2006 Phase 2 NCT00359736 United States;
Sildenafil (50 mg)
National Heart, Lung, and Blood Institute (NHLBI)
2004 Phase 2 NCT00352482 United States;
Sildenafil Citrate
Duke University
2007 Phase 3 NCT00517933 United States;
Sildenafil and Losartan
Alicia Gerke
2009 Phase 2/Phase 3 NCT00981747 United States;
Simtuzumab
Gilead Sciences
2013 Phase 2 NCT01769196 Australia;Belgium;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Switzerland;United Kingdom;United States;
2012 Phase 2 NCT01759511 United States;
Gilead Sciences, Inc.
2013 Phase 2 EUCTR2012-001571-36-GB Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2012-001571-36-CZ Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2012-001571-36-BE Australia;Belgium;Canada;Czech Republic;France;Germany;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Poland;Spain;Switzerland;United Kingdom;United States;
2013 - EUCTR2012-001571-36-PL Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2013 - EUCTR2012-001571-36-IT Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2013 - EUCTR2012-001571-36-ES Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2013 - EUCTR2012-001571-36-DE Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
Sirolimus
University of Virginia
2011 - NCT01462006 United States;
Sivelestat
Japanese Northern East Area Thoracic Surgery Study Group (JNETS)
2013 Phase 3 JPRN-UMIN000021109 Japan;
Sterile Normal Saline for Intravenous Use
Black Tie Medical, Inc.
2020 Early Phase 1 NCT04326036 United States;
Steroid pulse therapy group
Yonsei University
2021 - NCT04996303 Korea, Republic of;
Sub-Study: Nintedanib
FibroGen
2013 Phase 2 NCT01890265 Australia;Bulgaria;Canada;India;New Zealand;South Africa;United States;
Sub-Study: Pirfenidone
FibroGen
2013 Phase 2 NCT01890265 Australia;Bulgaria;Canada;India;New Zealand;South Africa;United States;
Sulphamethoxazole
Norfolk and Norwich University Hospital NHS Foundation Trust
2014 Phase 3 EUCTR2014-004058-32-GB United Kingdom;
Symbicort
Maisonneuve-Rosemont Hospital
2011 Phase 2 NCT01432080 Canada;
TBC
Nitto Denko Corporation
2018 Phase 2 EUCTR2017-004919-39-DE Germany;Japan;United Kingdom;United States;
TD-1058
Theravance Biopharma
2020 Phase 1 NCT04589260 United Kingdom;
TD139
Galecto Biotech AB
2019 Phase 2 EUCTR2018-002664-73-IT Belgium;Canada;France;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002664-73-GB Belgium;Canada;France;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002664-73-FR Belgium;Canada;France;Germany;Israel;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002664-73-ES Belgium;Canada;France;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States;
TNX-650, rhuMAb anti-IL13, aIL-13, MILR1444A
F. Hoffmann-La Roche Ltd
2014 Phase 2 EUCTR2013-001163-24-BE Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2013-001163-24-PL Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2013-001163-24-IT Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2013-001163-24-GB Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2013-001163-24-FR Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2013-001163-24-ES Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2013-001163-24-DE Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
TR0311
Trevi Therapeutics, Inc.
2019 Phase 2 EUCTR2018-004744-31-GB United Kingdom;
TRACLEER
Actelion Pharmaceuticals LTD
2006 - EUCTR2006-001183-24-IT Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
Actelion Registration Ltd
2008 - EUCTR2007-001741-18-IT Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
TRK-250
Toray Industries, Inc
2018 Phase 1 NCT03727802 United States;
Tacrolimus
Peking Union Medical College Hospital
2019 Phase 4 ChiCTR1900027121 China;
Taladegib
Endeavor Biomedicines, Inc.
2021 Phase 2 NCT04968574 Australia;Malaysia;
Tetrandrine
The First People's Hospital of Yancheng
2020 Phase 0 ChiCTR2000030400 China;
Tetrathiomolybdate
University of Michigan
2003 Phase 1/Phase 2 NCT00189176 United States;
Thalidomide
Johns Hopkins University
2007 Phase 3 NCT00600028 United States;
2003 Phase 2 NCT00162760 United States;
Thalidomide Pharmion
University of Nottingham
2011 - EUCTR2010-023828-24-GB United Kingdom;
The Standard Steroid Treatment, Plasma Exchange and rituximab
University of Pittsburgh
2012 Phase 2 NCT01524068 United States;
Thiotepa
Paul Szabolcs
2018 Phase 1/Phase 2 NCT03500731 United States;
Tiotropium
Saitama Medical University
2009 - JPRN-UMIN000005793 Japan;
Tipelukast
MediciNova
2016 Phase 2 NCT02503657 United States;
Tracleer
ACTELION PHARMACEUTICALS LTD
2007 Phase 3 EUCTR2006-001183-24-SK Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-001183-24-GB Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-001183-24-ES Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2007 - EUCTR2006-001183-24-NL Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-001183-24-IE Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-001183-24-DK Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-001183-24-DE Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-001183-24-CZ Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-001183-24-AT Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2006 - EUCTR2006-001183-24-BE Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
- Phase 3 EUCTR2006-001183-24-FR Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom;
Actelion Pharmaceuticals Ltd
2009 - EUCTR2007-001741-18-AT Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-001741-18-GB Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-001741-18-FR Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-001741-18-NL Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-001741-18-IE Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-001741-18-ES Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-001741-18-DE Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-001741-18-CZ Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-001741-18-BE Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
Royal Brompton and Harefield NHS Trust
2007 - EUCTR2007-001645-17-GB United Kingdom;
Traditional Chinese Medicine Formulation
Xuzhou Traditional Chinese Medicine Hospital
2018 - NCT03711435 China;
Tralokinumab
MedImmune LLC
2012 Phase 2 NCT01629667 Australia;Canada;Israel;Korea, Republic of;Peru;United States;
Tralokinumab cohort 1
AstraZeneca
2014 Phase 2 NCT02036580 Japan;
Tralokinumab cohort 2
AstraZeneca
2014 Phase 2 NCT02036580 Japan;
Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
AstraZeneca
- Phase 2 JPRN-JapicCTI-142452 -
Treatment as Usual (TAU)
University of Alabama at Birmingham
2018 Phase 2 NCT03286556 United States;
Treprostinil
Rajan Saggar
2008 Phase 2 NCT00705133 United States;
Treprostinil Ultrasonic Nebulizer
United Therapeutics
2022 Phase 3 NCT05255991 -
2022 Phase 3 NCT04905693 -
2021 Phase 3 NCT04708782 United States;
Treprostinil sodium for inhalation
Lung Biotechnology PBC
2008 Phase 2 NCT00703339 United States;
Trimethoprim
Norfolk and Norwich University Hospital NHS Foundation Trust
2014 Phase 3 EUCTR2014-004058-32-GB United Kingdom;
VAY736
Novartis Pharma AG
2018 Phase 2 EUCTR2017-002667-17-IT Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002667-17-IE Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002667-17-GB Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002667-17-FR Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002667-17-DE Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
Novartis Pharmaceuticals
2017 Phase 2 NCT03287414 Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
VRP700
Verona Pharma plc
2013 - EUCTR2012-005794-31-GB United Kingdom;
Valganciclovir
Fernanda P Silveira, MD, MS
2021 Phase 2 NCT05041426 United States;
Vanderbilt University Medical Center
2018 Phase 1 NCT02871401 United States;
Vasoactive intestinal peptide
Mondobiotech Laboratories Anstalt
2006 - EUCTR2006-002174-22-DE Germany;
Vismodegib
Hoffmann-La Roche
2016 Phase 1 NCT02648048 Germany;United States;
2014 Phase 2 NCT02168530 Australia;France;Germany;Israel;Korea, Republic of;Mexico;Peru;United States;
Warfarin
Duke University
2009 Phase 3 NCT00957242 United States;
ZL-2102
Zai Lab Pty. Ltd.
2015 Phase 1 NCT02397005 Australia;
ZSP1603
Guangdong Raynovent Biotech Co., Ltd
2021 Phase 1/Phase 2 NCT05119972 China;
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
2018 Phase 1 NCT03619616 China;
Zileuton
University of Michigan
2001 Phase 2 NCT00262405 United States;
Ziritaxestat
Galapagos NV
2019 Phase 3 EUCTR2018-001406-29-HU Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
2019 Phase 3 EUCTR2018-001405-87-GR Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001405-87-GB Australia;Belgium;Brazil;Chile;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001405-87-DE Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001405-87-CZ Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001405-87-BE Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2018-001406-29-PL Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
2018 Phase 3 EUCTR2018-001405-87-DK Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
[18F]-FBA-A20FMDV2
GlaxoSmithKline
2017 Phase 1 NCT03069989 United Kingdom;
[18F]FP-R01-MG-F2
Stanford University
2017 Early Phase 1 NCT03183570 United States;
[68Ga]CBP8
Massachusetts General Hospital
2018 Phase 1 NCT03535545 United States;
Medizinische Universität Wien, Univ.Klinik f.Radiodiagnostik
2010 - EUCTR2010-020223-44-AT Austria;
00258901
F. HOFFMANN - LA ROCHE LTD.
2016 Phase 2 EUCTR2015-005131-40-IT Belgium;Canada;Czech Republic;Czechia;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
00322900
F. HOFFMANN - LA ROCHE LTD.
2016 Phase 2 EUCTR2015-005131-40-IT Belgium;Canada;Czech Republic;Czechia;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
18F-FDG
Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui
2007 - JPRN-UMIN000010498 Japan;
3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt
Vicore Pharma AB
2020 Phase 2 EUCTR2020-000822-24-GB Ukraine;United Kingdom;
534-1508
F. Hoffmann-La Roche Ltd
2016 Phase 4 EUCTR2015-003280-11-NL Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
2016 Phase 4 EUCTR2015-003280-11-DK Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
2016 Phase 4 EUCTR2015-003280-11-DE Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
Roche Farma S.A., que representa en España a F. Hoffmann-La Roche Ltd
2015 Phase 4 EUCTR2015-003280-11-ES Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
68Ga-BMV101
Peking Union Medical College Hospital
2015 Early Phase 1 NCT02485886 China;
ACT-064992
ACTELION Pharmaceuticals Ltd.
2011 - EUCTR2010-024211-13-SI Australia;Canada;Germany;Israel;Slovenia;South Africa;Spain;Sweden;Turkey;United States;
2011 - EUCTR2010-024211-13-SE Australia;Canada;Germany;Israel;South Africa;Spain;Sweden;Turkey;United States;
2011 - EUCTR2010-024211-13-ES Australia;Canada;Germany;Israel;South Africa;Spain;Sweden;Turkey;United States;
2011 - EUCTR2010-024211-13-DE Australia;Canada;Germany;Israel;South Africa;Spain;Sweden;Turkey;United States;
Actelion Pharamceuticals Ltd
2010 - EUCTR2008-006054-17-IT France;Germany;Italy;Slovenia;Spain;Sweden;
Actelion Pharmaceuticals Ltd.
2009 Phase 2 EUCTR2008-006054-17-ES France;Germany;Italy;Slovenia;Spain;Sweden;
2009 - EUCTR2008-006054-17-SI France;Germany;Italy;Slovenia;Spain;Sweden;
2009 - EUCTR2008-006054-17-SE France;Germany;Italy;Slovenia;Spain;Sweden;
2009 - EUCTR2008-006054-17-FR France;Germany;Italy;Slovenia;Spain;Sweden;
- - EUCTR2008-006054-17-DE France;Germany;Italy;Slovenia;Spain;Sweden;
ACT-064992 (macitentan)
Actelion
2009 Phase 2 NCT00903331 Australia;Canada;France;Germany;Israel;Italy;Slovenia;South Africa;Spain;Sweden;Turkey;United States;
AP01
Avalyn Pharma, Inc.
2021 Phase 2 EUCTR2020-005103-39-PL Australia;Czech Republic;Czechia;Netherlands;New Zealand;Poland;United Kingdom;
2021 Phase 2 EUCTR2020-005103-39-CZ Australia;Czech Republic;Czechia;Netherlands;New Zealand;Poland;United Kingdom;
ART-123
ASAHI KASEI PHARMA CORPORATION
2016 Phase 3 JPRN-JapicCTI-163326 -
Asahi Kasei Pharma Corporation
2016 Phase 3 NCT02739165 Japan;
AT 10
Makino Ryoko
2021 Phase 3 JPRN-jRCT2051210129 Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;South Korea;Spain;Sweden;
AZAPRED
Thorax National Institute
2005 - NCT00518310 Chile;
AZD5055
AstraZeneca
2021 Phase 1 NCT05134727 United States;
Acetylcysteine
Saitama Red Cross Hospital
2013 - JPRN-UMIN000016706 Japan;
Shanghai Pulmonary Hospital, Tongji University School of Medicine
2020 - ChiCTR2000031386 China;
Aerosol interferon-gamma
NYU Langone Health
2007 Phase 1 NCT00563212 United States;
Air
Department of Respiratory Medicine, Toho University Omori Medical Center, Tokyo
2009 - JPRN-UMIN000016045 Japan;
Grant for Research on Diffuse Lung Disease from the Ministry of Health, Labour and Welfare of Japan.
2015 - JPRN-UMIN000015508 Japan;
Alemtuzumab
Paul Szabolcs
2018 Phase 1/Phase 2 NCT03500731 United States;
AlloRx
The Foundation for Orthopaedics and Regenerative Medicine
2022 Phase 1 NCT05016817 Antigua and Barbuda;
Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)
Joshua M Hare
2013 Phase 1 NCT02013700 United States;
Ambrisentan
Gilead Sciences
2009 Phase 3 NCT00879229 Australia;Austria;Belgium;Canada;Germany;Ireland;Israel;Italy;United Kingdom;United States;
2008 Phase 3 NCT00768300 Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;France;Germany;Ireland;Israel;Italy;Mexico;Netherlands;Peru;Poland;Spain;Switzerland;United Kingdom;United States;
Gilead Sciences Incorporated
2010 - EUCTR2008-004405-34-CZ Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-004405-34-FR Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-004405-34-NL Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-004405-34-IT Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-004405-34-IE Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-004405-34-GB Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-004405-34-ES Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-004405-34-BE Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-004405-34-AT Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
- - EUCTR2008-004405-34-DE Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
Gilead Sciences, Inc
2009 - EUCTR2009-011169-98-GB Austria;Czech Republic;Germany;Italy;United Kingdom;
2009 - EUCTR2009-011169-98-DE Austria;Czech Republic;Germany;Italy;United Kingdom;
2009 - EUCTR2009-011169-98-AT Austria;Czech Republic;Germany;Italy;United Kingdom;
Gilead Sciences, Inc.
2011 - EUCTR2009-011169-98-CZ Austria;Czech Republic;Germany;Italy;United Kingdom;
Antimicrobial therapy: Co-trimoxazole or Doxycycline
Weill Medical College of Cornell University
2017 Phase 3 NCT02759120 United States;
Atezolizumab
KATO Terufumi
2019 Phase 2 JPRN-jRCTs031190084 Japan;
Auto-titrating oxygen system
Imperial College London
2014 - NCT02248064 United Kingdom;
Autoantibody Reductive Therapy
University of Alabama at Birmingham
2018 Phase 2 NCT03286556 United States;
Autologous Adipose Derived MSCs (ADMSCs)
Kasiak Research Pvt. Ltd.
2014 Phase 1/Phase 2 NCT02135380 India;
Autologous Stromal Vascular Fraction (SVF)
Kasiak Research Pvt. Ltd.
2014 Phase 1/Phase 2 NCT02135380 India;
Autologous mesenchymal stem cells derived from bone marrow
Clinica Universidad de Navarra, Universidad de Navarra
2013 Phase 1 NCT01919827 Spain;
Aviptadil, 66 microgram/mL
Mondobiotech Laboratories Anstalt
2006 - EUCTR2006-002174-22-DE Germany;
Azathioprine
InterMune
2002 Phase 3 NCT00052039 Italy;
Azathioprine/prednisone
University of Michigan
2001 Phase 2 NCT00262405 United States;
Azithromycin
Maisonneuve-Rosemont Hospital
2011 Phase 2 NCT01432080 Canada;
University Hospital Inselspital, Berne
2014 - NCT02173145 Switzerland;
BBT-877, Multiple doses
Bridge Biotherapeutics, Inc.
2019 Phase 1 NCT03830125 United States;
BBT-877, Single dose
Bridge Biotherapeutics, Inc.
2019 Phase 1 NCT03830125 United States;
BG00011
BIOGEN IDEC RESEARCH LIMITED
2018 Phase 2 EUCTR2017-003158-18-IT Argentina;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
Biogen
2018 Phase 2 NCT03573505 Argentina;Australia;Belgium;Chile;Czechia;Denmark;France;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2012 Phase 2 NCT01371305 United States;
Biogen Idec Research Limited
2019 Phase 2 EUCTR2017-003158-18-PL Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2019 Phase 2 EUCTR2017-003158-18-DE Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003158-18-NL Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003158-18-GR Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003158-18-GB Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003158-18-ES Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003158-18-DK Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003158-18-CZ Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003158-18-BE Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
BI 1015550
BOEHRINGER-INGELHEIM ITALIA S.P.A.
2020 Phase 2 EUCTR2019-004167-45-IT Australia;Austria;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Boehringer Ingelheim
2020 Phase 2 NCT04419506 Argentina;Australia;Austria;Canada;Chile;China;Czechia;Denmark;Finland;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004167-45-NL Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2018 Phase 1 NCT03422068 Belgium;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;United Kingdom;
Boehringer Ingelheim B.V.
2020 Phase 2 EUCTR2019-004167-45-DK Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Boehringer Ingelheim Finland Ky
2020 Phase 2 EUCTR2019-004167-45-FI Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Boehringer Ingelheim Limited
2020 Phase 2 EUCTR2019-004167-45-GB Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co. KG
2020 Phase 2 EUCTR2019-004167-45-DE Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Boehringer Ingelheim RCV GmbH & Co KG
2021 Phase 2 EUCTR2019-004167-45-CZ Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004167-45-SK Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004167-45-PL Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004167-45-HU Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004167-45-AT Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
BIBF 1120
BOEHRINGER ING.
2012 Phase 3 EUCTR2011-002766-21-IT Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
2011 - EUCTR2010-024251-87-IT Belgium;Czech Republic;Germany;Ireland;Italy;United Kingdom;
2010 Phase 2 EUCTR2009-013788-21-IT Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim
2012 Phase 3 NCT01619085 Australia;Belgium;Canada;Chile;China;Czech Republic;Czechia;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
2012 Phase 3 EUCTR2011-002766-21-FI Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
2011 Phase 3 NCT01335477 Canada;Chile;China;Finland;France;Germany;Greece;India;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United States;
2011 Phase 3 NCT01335464 Argentina;Australia;Belgium;Brazil;China;Czech Republic;France;Germany;India;Ireland;Israel;Italy;Japan;United Kingdom;United States;
2011 - EUCTR2010-024252-29-NL Finland;Germany;Greece;Netherlands;Portugal;Spain;
2011 - EUCTR2010-024252-29-GR Finland;Germany;Greece;Netherlands;Portugal;Spain;
2011 - EUCTR2010-024252-29-FI Finland;Germany;Greece;Netherlands;Portugal;Spain;
2010 Phase 2 NCT01170065 Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;El Salvador;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;
2010 Phase 2 NCT01136174 Japan;
2008 - EUCTR2006-002875-42-GR Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2007 Phase 2 EUCTR2006-002875-42-GB Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2007 - EUCTR2006-002875-42-IE Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2007 - EUCTR2006-002875-42-DE Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
Boehringer Ingelheim Hellas
2012 Phase 3 EUCTR2011-002766-21-GR Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
Boehringer Ingelheim Ellas AE
2010 - EUCTR2009-013788-21-GR Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim España S.A
2012 Phase 3 EUCTR2011-002766-21-ES Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
Boehringer Ingelheim España S.A.
2010 - EUCTR2009-013788-21-ES Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim España, S.A.
2011 Phase 3 EUCTR2010-024252-29-ES Canada;Chile;China;Finland;France;Germany;Greece;India;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United States;
2007 - EUCTR2006-002875-42-ES Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
Boehringer Ingelheim France
2011 - EUCTR2010-024252-29-PT Canada;China;Finland;France;Germany;Greece;India;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;United States;
2010 Phase 2 EUCTR2009-013788-21-FR Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
2008 - EUCTR2006-002875-42-PT Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
Boehringer Ingelheim France SAS
2007 Phase 2 EUCTR2006-002875-42-FR Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
Boehringer Ingelheim Limited
2013 Phase 3 EUCTR2011-002766-21-IE Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
2012 Phase 3 EUCTR2011-002766-21-GB Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
2011 Phase 3 EUCTR2010-024251-87-GB Belgium;Czech Republic;Germany;Ireland;Italy;United Kingdom;
2011 - EUCTR2010-024251-87-IE Belgium;Czech Republic;Germany;Ireland;Italy;United Kingdom;
2010 Phase 2 EUCTR2009-013788-21-GB Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim Ltd
2010 Phase 2 EUCTR2009-013788-21-IE Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim Pharma Ges mbH
2008 - EUCTR2006-002875-42-BG Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2007 - EUCTR2006-002875-42-CZ Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
Boehringer Ingelheim Pharma GmbH & Co. KG
2012 Phase 3 EUCTR2011-002766-21-DE Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
2011 - EUCTR2010-024252-29-DE Canada;Chile;China;Finland;France;Germany;Greece;India;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United States;
2011 - EUCTR2010-024251-87-DE Argentina;Australia;Belgium;Brazil;China;Czech Republic;France;Germany;India;Ireland;Israel;Italy;Japan;United Kingdom;United States;
2010 Phase 2 EUCTR2009-013788-21-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;
Boehringer Ingelheim RCV Ges mbH & Co KG
2007 - EUCTR2006-002875-42-HU Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
Boehringer Ingelheim RCV GmBH & Co KG
2011 - EUCTR2010-024251-87-CZ Argentina;Australia;Belgium;Brazil;China;Czech Republic;Germany;India;Ireland;Israel;Italy;Japan;United Kingdom;United States;
2010 Phase 2 EUCTR2009-013788-21-HU Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
2010 - EUCTR2009-013788-21-BG Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim RCV GmbH & Co KG
2012 Phase 3 EUCTR2011-002766-21-CZ Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
2010 Phase 2 EUCTR2009-013788-21-CZ Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Russian Federation;Spain;United Kingdom;
Boehringer Ingelheim bv
2007 - EUCTR2006-002875-42-NL Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
SCS Boehringer Ingelheim Comm.V
2011 Phase 3 EUCTR2010-024251-87-BE Argentina;Australia;Belgium;Brazil;China;Czech Republic;France;Germany;India;Ireland;Israel;Italy;Japan;United Kingdom;United States;
2010 Phase 2 EUCTR2009-013788-21-BE Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
2007 - EUCTR2006-002875-42-BE Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
SCS Boehringer Ingelheim Ingelheim Comm.V
2012 Phase 3 EUCTR2011-002766-21-BE Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
Unilfarma - União Internacional de Lab. Farmacêuticos, Lda
2012 Phase 3 EUCTR2011-002766-21-PT Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
Unilfarma, Lda.
2010 Phase 2 EUCTR2009-013788-21-PT Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
BIBF 1120 ES
BOEHRINGER ING.
2007 - EUCTR2006-002875-42-IT Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
BIBF1120
Boehringer Ingelheim España, S.A.
2011 Phase 3 EUCTR2010-024252-29-ES Canada;Chile;China;Finland;France;Germany;Greece;India;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United States;
BLD-2660
Blade Therapeutics
2019 Phase 2 NCT04244825 United Kingdom;
Blade Therapeutics, Inc.
2020 Phase 2 EUCTR2019-004998-34-GB United Kingdom;
BMS-986020
Bristol-Myers Squibb
2013 Phase 2 NCT01766817 Australia;Chile;Colombia;Mexico;Peru;United States;
BMS-986278
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2020 Phase 2 EUCTR2019-003992-21-IT Argentina;Australia;Belgium;Brazil;Canada;Chile;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Spain;Taiwan;United Kingdom;United States;
Bristol-Myers Squibb
2019 Phase 1 NCT03981094 United States;
Bristol-Myers Squibb International Corporation
2020 Phase 2 EUCTR2019-003992-21-DE Argentina;Australia;Belgium;Brazil;Canada;Chile;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003992-21-BE Argentina;Australia;Belgium;Brazil;Canada;Chile;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Bardoxolone methyl
Reata Pharmaceuticals, Inc.
2014 Phase 2 NCT02036970 Germany;Spain;United Kingdom;United States;
Beclometasone dipropionate
Hull and East Yorkshire Hospitals NHS Trust
2014 - EUCTR2013-004404-19-GB United Kingdom;
Bevacizumab
IP lung cancer study group
2012 - JPRN-UMIN000018322 Japan;
Katakami Nobuyuki
2013 Phase 2 JPRN-jRCTs061180046 Japan;
Blood sample collection
Rennes University Hospital
2014 - NCT04016168 France;
Bone marrow mesenchymal stem cells
Federal Research Clinical Center of Federal Medical & Biological Agency, Russia
2013 Phase 1/Phase 2 NCT02594839 Russian Federation;
Bosentan
Actelion
2008 Phase 3 NCT00631475 Australia;Austria;Belgium;Canada;Croatia;Czech Republic;Former Serbia and Montenegro;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Serbia;Spain;Switzerland;United Kingdom;United States;
2007 Phase 3 NCT00391443 Australia;Austria;Belgium;Canada;Croatia;Czech Republic;Denmark;Former Serbia and Montenegro;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Serbia;Slovakia;Spain;Switzerland;United Kingdom;United States;
2003 Phase 2/Phase 3 NCT00071461 Canada;France;Germany;Israel;Italy;Switzerland;United Kingdom;United States;
Actelion Registration Ltd
2008 - EUCTR2007-001741-18-IT Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
Department of Respiratory Medicine, Chiba-Hokusoh Hospital, Nippon Medical School
2011 - JPRN-UMIN000004749 Japan;
Rajan Saggar
2007 Phase 4 NCT00625469 United States;
Royal Brompton & Harefield NHS Foundation Trust
2008 Phase 4 NCT00637065 United Kingdom;
Broncho-Vaxom
Shanghai Pulmonary Hospital
2015 - ChiCTR-OOC-15005840 China;
Bronchoalveolar lavage (BAL fluid)
McGill University Health Centre/Research Institute of the McGill University Health Centre
2021 - NCT05007340 Canada;
C21
Vicore Pharma AB
2020 Phase 2 NCT04533022 India;Russian Federation;Ukraine;United Kingdom;
2020 Phase 2 EUCTR2020-000822-24-GB Ukraine;United Kingdom;
2018 Phase 2 EUCTR2017-004923-63-GB Bulgaria;Poland;Serbia;United Kingdom;
CBDCA
Lung Oncology Group in Kyushu, Japan (LOGIK)
2007 - JPRN-UMIN000015929 Japan;
CC-90001
Celgene
2017 Phase 2 NCT03142191 Australia;Brazil;Canada;China;Colombia;Germany;Greece;Romania;Russian Federation;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Celgene Corporation
2017 Phase 2 EUCTR2016-003473-17-GR Australia;Brazil;Canada;Colombia;France;Germany;Greece;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003473-17-GB Australia;Brazil;Canada;Colombia;France;Germany;Greece;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
CC-930
Celgene
2011 Phase 2 NCT01203943 Canada;United States;
CD3/CD19 negative hematopoietic stem cells
Paul Szabolcs
2018 Phase 1/Phase 2 NCT03500731 United States;
CNTO 888
Centocor, Inc.
2008 Phase 2 NCT00786201 Belgium;Canada;Germany;Netherlands;United States;
CNTO888
Centocor B.V.
2009 - EUCTR2008-001281-86-NL Belgium;Germany;Netherlands;
Janssen Biologics B.V.
2010 - EUCTR2008-001281-86-DE Belgium;Germany;Netherlands;
2009 Phase 2 EUCTR2008-001281-86-BE Belgium;Germany;Netherlands;
COMPOUND 21
Vicore Pharma AB
2018 Phase 2 EUCTR2017-004923-63-GB Bulgaria;Poland;Serbia;United Kingdom;
CSL312
CSL Behring
2022 Phase 2 NCT05130970 Canada;United States;
Carboplatin
Fujimoto Daichi
2021 - JPRN-jRCTs051200109 Japan;
Hirosaki University Graduate School of Medicine
2016 - JPRN-UMIN000021591 Japan;
IKEDA Satoshi
2019 Phase 2 JPRN-jRCTs031190119 Japan;
IP lung cancer study group
2012 - JPRN-UMIN000018322 Japan;
2012 - JPRN-UMIN000018248 Japan;
Katakami Nobuyuki
2013 Phase 2 JPRN-jRCTs061180046 Japan;
2013 Phase 2 JPRN-jRCTs051180149 Japan;
Lung Oncology Group in Kyushu, Japan (LOGIK)
2007 - JPRN-UMIN000015929 Japan;
Okamoto Isamu
2017 Phase 3 JPRN-jRCTs071180049 Japan;
Research Institute for Diseases of the Chest, Kyushu University
2017 Phase 3 JPRN-UMIN000026799 Japan;
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)
Lung Therapeutics, Inc
2020 Phase 1 NCT04233814 United Kingdom;
Centricyte 1000
Black Tie Medical, Inc.
2020 Early Phase 1 NCT04326036 United States;
Combination Product: EGCG + Nintedanib
Hal Chapman
2022 Phase 1 NCT05195918 United States;
Combination Product: EGCG + Pirfenidone
Hal Chapman
2022 Phase 1 NCT05195918 United States;
Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids
Michael Donahoe
2011 Phase 1/Phase 2 NCT01266317 United States;
Corticosteroid (prednisolone)
Assistance Publique - Hôpitaux de Paris
2015 Phase 3 NCT02460588 France;
Cotrimoxazole
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2013 Phase 3 NCT01777737 Spain;
Norfolk and Norwich University Hospital NHS Foundation Trust
2014 Phase 3 EUCTR2014-004058-32-GB United Kingdom;
Cravit
Respiratory Department, Peking Union Medical College Hospital
2011 - ChiCTR-TRC-12002372 China;
Cromolyn Sodium
University of California, San Francisco
2015 Phase 1 NCT01841307 United States;
Cromolyn sodio (cromoglicato disodico, DSCG)
Respivant Sciences, GmbH
2019 Phase 2 EUCTR2018-004447-23-IT Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
Cromolyn sodium [Disodium Cromoglycate]
Respivant Sciences GmbH
2019 Phase 2 EUCTR2018-004447-23-NL Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004447-23-GB Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004447-23-DE Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;Turkey;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004447-23-CZ Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004447-23-BE Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
Cyclophosphamide
Assistance Publique - Hôpitaux de Paris
2015 Phase 3 NCT02460588 France;
Peking Union Medical College Hospital
2019 Phase 4 ChiCTR1900027121 China;
Cyclosphamine
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2015 Phase 3 EUCTR2015-000492-27-FR France;
DEX284
Galecto Biotech AB
2020 Phase 2 EUCTR2018-002664-73-IE Australia;Belgium;Canada;France;Georgia;Germany;Ireland;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002664-73-PL Australia;Belgium;Canada;France;Georgia;Germany;Ireland;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002664-73-IT Belgium;Canada;France;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002664-73-GB Belgium;Canada;France;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002664-73-FR Belgium;Canada;France;Germany;Israel;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002664-73-ES Belgium;Canada;France;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States;
DWN12088
Daewoong Pharmaceutical Co. LTD.
2021 Phase 1 NCT04888728 Korea, Republic of;
2021 Phase 1 NCT04888715 Korea, Republic of;
Dabigatran
University College, London
2016 - NCT02885961 -
Dasatinib + Quercetin
Wake Forest University Health Sciences
2016 Phase 1 NCT02874989 United States;
Dextromethorphan
Tianjin Medical University General Hospital
2020 Phase 4 ChiCTR2000037602 China;
Diet A group
Daewoong Pharmaceutical Co. LTD.
2021 Phase 1 NCT04767815 Korea, Republic of;
Diet B group
Daewoong Pharmaceutical Co. LTD.
2021 Phase 1 NCT04767815 Korea, Republic of;
Diet C group
Daewoong Pharmaceutical Co. LTD.
2021 Phase 1 NCT04767815 Korea, Republic of;
Disodium Cromoglycate [cromolyn sodium]
Patara Pharma
2015 - EUCTR2014-004025-40-NL Netherlands;United Kingdom;
2014 Phase 2 EUCTR2014-004025-40-GB Netherlands;United Kingdom;
Disodium cromoglycate (DSCG)
Patara Pharma
2015 - EUCTR2014-004025-40-NL Netherlands;United Kingdom;
2014 Phase 2 EUCTR2014-004025-40-GB Netherlands;United Kingdom;
Durvalumab
Fujimoto Daichi
2021 - JPRN-jRCTs051200109 Japan;
ESBRIET - 267 MG - CAPSULA RIGIDA - USO ORALE - FLACONE (HDPE) 270 CAPSULE
F. HOFFMANN - LA ROCHE LTD.
2015 Phase 4 EUCTR2015-003280-11-IT Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
EZ-2053
Neovii Biotech
2005 Phase 3 NCT00105183 Australia;Austria;Canada;United States;
Endobronchial infusion of adult mesenchymal stem cells
Clinica Universidad de Navarra, Universidad de Navarra
2013 Phase 1 NCT01919827 Spain;
Epigallocatechin-3-gallate (EGCG)
University of California, San Francisco
2018 Early Phase 1 NCT03928847 United States;
Erivedge
F. Hoffmann-La Roche Ltd.
2014 - EUCTR2014-000963-42-DE Australia;Chile;France;Germany;Israel;Italy;Korea, Republic of;Mexico;New Zealand;Peru;Spain;United States;
Esbriet
BOEHRINGER-INGELHEIM ITALIA S.P.A.
2015 Phase 4 EUCTR2015-000640-42-IT Canada;France;Germany;Italy;Netherlands;United States;
Boehringer Ingelheim France
2015 Phase 4 EUCTR2015-000640-42-FR Canada;France;Germany;Italy;Netherlands;United States;
Boehringer Ingelheim Pharma GmbH & Co.KG
2015 Phase 4 EUCTR2015-000640-42-DE Canada;France;Germany;Italy;Netherlands;United States;
Boehringer Ingelheim bv
2015 Phase 4 EUCTR2015-000640-42-NL Canada;France;Germany;Italy;Netherlands;United States;
F. Hoffmann-La Roche Ltd
2017 Phase 2 EUCTR2015-005131-40-HU Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2017 Phase 2 EUCTR2015-005131-40-CZ Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 4 EUCTR2015-003280-11-NL Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
2016 Phase 4 EUCTR2015-003280-11-DK Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
2016 Phase 4 EUCTR2015-003280-11-DE Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
2016 Phase 2 EUCTR2015-005131-40-NL Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 2 EUCTR2015-005131-40-GR Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 2 EUCTR2015-005131-40-ES Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 2 EUCTR2015-005131-40-DE Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 2 EUCTR2015-005131-40-BE Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
Roche Farma S.A., que representa en España a F. Hoffmann-La Roche Ltd
2015 Phase 4 EUCTR2015-003280-11-ES Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
Esbriet® (Pirfenidon)
Justus Liebig Universität Giessen
2015 Phase 2 EUCTR2014-000861-32-DE Germany;
Etanercept
Wyeth is now a wholly owned subsidiary of Pfizer
2003 Phase 2 NCT00063869 United States;
Etoposide
Fujimoto Daichi
2021 - JPRN-jRCTs051200109 Japan;
IKEDA Satoshi
2019 Phase 2 JPRN-jRCTs031190119 Japan;
FG-3019
FIBROGEN
2020 Phase 3 EUCTR2020-000697-22-IT Belgium;Brazil;Bulgaria;Colombia;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;India;Ireland;Italy;Lebanon;Mexico;Netherlands;Norway;Peru;Poland;Serbia;Spain;Ukraine;United Kingdom;
FibroGen
2011 Phase 2 NCT01262001 United States;
1994 Phase 1 NCT00074698 United States;
FibroGen, Inc.
2021 Phase 3 EUCTR2020-000697-22-IE Brazil;Colombia;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;Ireland;Italy;Lebanon;Mexico;Netherlands;Peru;Poland;Serbia;Spain;Switzerland;Ukraine;United Kingdom;
2020 Phase 3 EUCTR2020-000697-22-NL Brazil;Colombia;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;Ireland;Italy;Lebanon;Mexico;Netherlands;Peru;Poland;Serbia;Spain;Switzerland;Ukraine;United Kingdom;
2020 Phase 3 EUCTR2020-000697-22-HU Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;India;Ireland;Italy;Lebanon;Mexico;Netherlands;Norway;Peru;Poland;Serbia;Spain;Ukraine;United Kingdom;
2020 Phase 3 EUCTR2020-000697-22-DK Brazil;Colombia;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;Ireland;Italy;Lebanon;Mexico;Netherlands;Peru;Poland;Serbia;Spain;Switzerland;Ukraine;United Kingdom;
2020 Phase 3 EUCTR2020-000697-22-DE Brazil;Colombia;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;Ireland;Italy;Lebanon;Mexico;Netherlands;Peru;Poland;Serbia;Spain;Switzerland;Ukraine;United Kingdom;
FG-3019 10mg/mL in 10 mL vials
FibroGen, Inc.
2016 Phase 2 EUCTR2014-005658-20-BG Australia;Bulgaria;Canada;India;New Zealand;South Africa;United States;
FLUORINE (18F) FLUDEOXYGLUCOSE
Medizinische Universität Wien, Univ.Klinik f.Radiodiagnostik
2010 - EUCTR2010-020223-44-AT Austria;
Fludarabine
Paul Szabolcs
2018 Phase 1/Phase 2 NCT03500731 United States;
Fluimucil® 600 mg effervescent tablets
InterMune International AG.
2013 Phase 2 EUCTR2012-000564-14-GB Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
2013 - EUCTR2012-000564-14-SE Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
2013 - EUCTR2012-000564-14-IT Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
2013 - EUCTR2012-000564-14-DK Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
2013 - EUCTR2012-000564-14-DE Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
2013 - EUCTR2012-000564-14-BE Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
2013 - EUCTR2012-000564-14-AT Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
Formoterol fumarate dihydrate
Hull and East Yorkshire Hospitals NHS Trust
2014 - EUCTR2013-004404-19-GB United Kingdom;
Fostair
Hull University Teaching Hospitals NHS Trust
2014 Phase 2 NCT02048644 United Kingdom;
Hull and East Yorkshire Hospitals NHS Trust
2014 - EUCTR2013-004404-19-GB United Kingdom;
G-CSF
Paul Szabolcs
2018 Phase 1/Phase 2 NCT03500731 United States;
G048E03
F. HOFFMANN - LA ROCHE LTD.
2016 Phase 2 EUCTR2015-005131-40-IT Belgium;Canada;Czech Republic;Czechia;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
G321605
Galapagos NV
2019 Phase 2 EUCTR2017-004302-18-HR Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
2019 Phase 2 EUCTR2017-004302-18-FI Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
2018 Phase 2 EUCTR2017-004302-18-SK Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
2018 Phase 2 EUCTR2017-004302-18-SE Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
2018 Phase 2 EUCTR2017-004302-18-FR Bulgaria;Croatia;Egypt;Finland;France;Lebanon;Oman;Romania;Slovakia;Sweden;Ukraine;
2018 Phase 2 EUCTR2017-004302-18-BG Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
G451990
GALAPAGOS NV
2018 Phase 3 EUCTR2018-001406-29-IT Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
2016 Phase 2 EUCTR2015-004157-41-IT Italy;United Kingdom;
Galapagos NV
2019 Phase 3 EUCTR2018-001406-29-NL Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
2019 Phase 3 EUCTR2018-001406-29-HU Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
2019 Phase 3 EUCTR2018-001406-29-FR Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
2019 Phase 3 EUCTR2018-001405-87-GR Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001405-87-GB Australia;Belgium;Brazil;Chile;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001405-87-DE Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001405-87-CZ Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001405-87-BE Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2018-001406-29-PL Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
2018 Phase 3 EUCTR2018-001405-87-ES Australia;Belgium;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2018-001405-87-DK Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004157-41-GB Ukraine;United Kingdom;
GB0139
Galecto Biotech AB
2019 Phase 2 NCT03832946 Australia;Belgium;Canada;France;Georgia;Germany;Ireland;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
GB0139 (previously known as TD139)
Galecto Biotech AB
2020 Phase 2 EUCTR2018-002664-73-IE Australia;Belgium;Canada;France;Georgia;Germany;Ireland;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002664-73-PL Australia;Belgium;Canada;France;Georgia;Germany;Ireland;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
GBT440
Global Blood Therapeutics
2016 Phase 2 NCT02989168 United Kingdom;United States;
2016 Phase 2 NCT02846324 United States;
GBT440 300 mg capsule
Global Blood Therapeutics Inc.
2017 Phase 2 EUCTR2017-001276-27-GB United Kingdom;United States;
GBT440 300 mg tablet
Global Blood Therapeutics Inc.
2017 Phase 2 EUCTR2017-001276-27-GB United Kingdom;United States;
GC1008
Genzyme, a Sanofi Company
2005 Phase 1 NCT00125385 Belgium;United States;
GKT137831
University of Alabama at Birmingham
2020 Phase 2 NCT03865927 United States;
GLPG1205
Galapagos NV
2019 Phase 2 EUCTR2017-004302-18-HR Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
2019 Phase 2 EUCTR2017-004302-18-FI Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
2018 Phase 2 NCT03725852 Bulgaria;Croatia;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
2018 Phase 2 EUCTR2017-004302-18-SK Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
2018 Phase 2 EUCTR2017-004302-18-SE Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
2018 Phase 2 EUCTR2017-004302-18-FR Bulgaria;Croatia;Egypt;Finland;France;Lebanon;Oman;Romania;Slovakia;Sweden;Ukraine;
2018 Phase 2 EUCTR2017-004302-18-BG Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
GLPG1690
GALAPAGOS NV
2018 Phase 3 EUCTR2018-001406-29-IT Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
2016 Phase 2 EUCTR2015-004157-41-IT Italy;United Kingdom;
Galapagos NV
2019 Phase 3 EUCTR2018-001406-29-NL Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
2019 Phase 3 EUCTR2018-001406-29-HU Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
2019 Phase 3 EUCTR2018-001406-29-FR Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
2019 Phase 3 EUCTR2018-001405-87-GR Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001405-87-GB Australia;Belgium;Brazil;Chile;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001405-87-DE Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001405-87-CZ Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001405-87-BE Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 NCT03733444 Argentina;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
2018 Phase 3 NCT03711162 Australia;Belgium;Brazil;Chile;Czechia;Denmark;Germany;Greece;Japan;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2018-001406-29-PL Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
2018 Phase 3 EUCTR2018-001405-87-ES Australia;Belgium;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2018-001405-87-DK Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004157-41-GB Ukraine;United Kingdom;
GLPG1690 600 mg QD
Galapagos NV
2016 Phase 2 NCT02738801 Italy;Ukraine;United Kingdom;
GS-6624
Gilead Sciences
2010 Phase 1 NCT01362231 United States;
Gilead Sciences, Inc.
2013 Phase 2 EUCTR2012-001571-36-GB Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2012-001571-36-CZ Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2012-001571-36-BE Australia;Belgium;Canada;Czech Republic;France;Germany;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Poland;Spain;Switzerland;United Kingdom;United States;
2013 - EUCTR2012-001571-36-PL Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2013 - EUCTR2012-001571-36-IT Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2013 - EUCTR2012-001571-36-ES Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2013 - EUCTR2012-001571-36-DE Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
GSK2126458
GlaxoSmithKline
2013 Phase 1 NCT01725139 United Kingdom;
GSK3008348
GlaxoSmithKline
2017 Phase 1 NCT03069989 United Kingdom;
GSK3008348 Nebuliser solution
GlaxoSmithKline
2015 Phase 1 NCT02612051 United Kingdom;
Gallium68-Dota-Noc
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
2012 - EUCTR2011-003687-78-IT Italy;
2009 - EUCTR2008-007168-40-IT Italy;
Gefapixant
Afferent Pharmaceuticals, Inc.
2015 Phase 2 NCT02502097 United States;
2015 Phase 2 NCT02477709 United States;
Granulocyte Colony Stimulating Factor
Shanghai Pulmonary Hospital
2015 - ChiCTR-OOC-15005862 China;
HEC 68498
Sunshine Lake Pharma Co., Ltd.
2018 Phase 1 NCT03502902 United States;
HEC585
Sunshine Lake Pharma Co., Ltd.
2020 Phase 1 NCT04512170 China;
2017 Phase 1 NCT03092102 United States;
HZN-825
Horizon Therapeutics Ireland DAC
2022 Phase 2 EUCTR2021-001253-32-GR Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Italy;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States;
2022 Phase 2 EUCTR2021-001253-32-ES Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Italy;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 2 NCT05032066 United States;
High dose BIBF 1120 twice daily
Boehringer Ingelheim
2007 Phase 2 NCT00514683 Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;El Salvador;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;South Africa;Spain;Taiwan;Turkey;United Kingdom;
Humanized anti-alpha v beta 6 mAb
BIOGEN IDEC RESEARCH LIMITED
2018 Phase 2 EUCTR2017-003158-18-IT Argentina;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
Biogen Idec Research Limited
2019 Phase 2 EUCTR2017-003158-18-PL Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2019 Phase 2 EUCTR2017-003158-18-DE Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003158-18-NL Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003158-18-GR Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003158-18-GB Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003158-18-ES Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003158-18-DK Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003158-18-CZ Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003158-18-BE Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
Hydroxyurea
Paul Szabolcs
2018 Phase 1/Phase 2 NCT03500731 United States;
Hyperoxia
University of British Columbia
2022 - NCT03800017 -
Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment
Duke University
2020 Phase 2 NCT04071769 United States;
Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment
Duke University
2022 Phase 2 NCT05241275 -
Hyperpolarized 129-Xenon gas
Bastiaan Driehuys
2015 Phase 1 NCT02478268 United States;
Hyperpolarized Xe129
University of Kansas Medical Center
2022 Phase 2 NCT04677426 -
IDL-2965 Oral Capsule
Indalo Therapeutics, Inc.
2019 Phase 1 NCT03949530 United Kingdom;
INO
Bellerophon Pulse Technologies LLC
2014 Phase 1;Phase 2 EUCTR2014-003423-21-BE Belgium;
INOmax 400ppm mol/mol inhalation gas
Bellerophon Pulse Technologies LLC
2014 Phase 1;Phase 2 EUCTR2014-003423-21-BE Belgium;
INS018_055
InSilico Medicine Hong Kong Limited
2022 Phase 1 NCT05154240 New Zealand;
IV Deployment Of cSVF In Sterile Normal Saline IV Solution
Black Tie Medical, Inc.
2020 Early Phase 1 NCT04326036 United States;
IW001
ImmuneWorks
2010 Phase 1 NCT01199887 United States;
Ifenprodil
Algernon Pharmaceuticals
2020 Phase 2 NCT04318704 Australia;New Zealand;
Iloprost Inhalation Solution (Ventavis)
Actelion
2005 Phase 2 NCT00109681 United States;
Imatinib Mesylate (Gleevec)
Daniels, Craig E., M.D.
2003 Phase 2/Phase 3 NCT00131274 -
Immukin
InterMune
2005 Phase 3 EUCTR2004-001261-17-IE Ireland;
2005 Phase 3 EUCTR2004-000029-31-IE Ireland;
Inhaled Nitric Oxide
Geno LLC
2011 Phase 2 NCT01265888 United States;
Inhaled Nitric Oxide - 30 mcg/kg IBW/hr
Bellerophon
2015 Phase 1 NCT02267655 Belgium;
Inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr
Bellerophon
2015 Phase 1 NCT02267655 Belgium;
Inhaled TD139
Galecto Biotech AB
2014 Phase 1/Phase 2 NCT02257177 United Kingdom;
Inhaled Treprostinil
United Therapeutics
2022 Phase 3 NCT05255991 -
2022 Phase 3 NCT04905693 -
2021 Phase 3 NCT04708782 United States;
Inhaled carbon monoxide
Brigham and Women's Hospital
2011 Phase 2 NCT01214187 United States;
Inhaled nitric oxide 75 mcg/kg IBW/hr
Bellerophon
2015 Phase 1 NCT02267655 Belgium;
Interferon alpha oral lozenge
Texas Tech University Health Sciences Center
2000 Phase 2 NCT01442779 United States;
Interferon gamma-1b
InterMune
2005 Phase 3 EUCTR2004-001261-17-IE Ireland;
2005 Phase 3 EUCTR2004-000029-31-IE Ireland;
2003 Phase 3 NCT00076635 United States;
Interferon gamma-1b (Actimmune)
InterMune
2003 Phase 3 NCT00075998 United States;
Interferon-alpha lozenges
Amarillo Biosciences, Inc.
2008 Phase 2 NCT00690885 United States;
Interferon-gamma 1b
InterMune
2002 Phase 3 NCT00052039 Italy;
2002 Phase 2 NCT00052052 United States;
2001 Phase 2 NCT00047658 United States;
2000 Phase 3 NCT00047645 United States;
Intermediate dose BIBF 1120 twice daily
Boehringer Ingelheim
2007 Phase 2 NCT00514683 Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;El Salvador;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;South Africa;Spain;Taiwan;Turkey;United Kingdom;
Jaktinib Dihydrochloride Monohydrate 50mg BID and Mimic tablets of jakitinib hydrochloride 75mg BID and Acetylcysteine Effervescent Tablets
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2020 Phase 2 NCT04312594 China;
Jaktinib Dihydrochloride Monohydrate 75mg BID and Mimic tablets of jakitinib hydrochloride 50mg BID and Acetylcysteine Effervescent Tablets
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2020 Phase 2 NCT04312594 China;
Jin-shui Huan-xian granule
Henan University of Traditional Chinese Medicine
2020 - NCT04187690 China;
KD025
Kadmon Corporation, LLC
2016 Phase 2 NCT02688647 United States;
L - Antineoplastic and immunomodulating agents
Boehringer Ingelheim
2017 - NCT03281200 Spain;
L01 - Antineoplastic agents
Boehringer Ingelheim
2017 - NCT03281200 Spain;
L01X - Other antineoplastic agents
Boehringer Ingelheim
2017 - NCT03281200 Spain;
L01XE - Protein kinase inhibitors
Boehringer Ingelheim
2017 - NCT03281200 Spain;
L01XE31 - Nintedanib
Boehringer Ingelheim
2017 - NCT03281200 Spain;
LANREOTIDE ACETATE
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
2012 - EUCTR2011-003687-78-IT Italy;
LPA1
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2020 Phase 2 EUCTR2019-003992-21-IT Argentina;Australia;Belgium;Brazil;Canada;Chile;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Spain;Taiwan;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2020 Phase 2 EUCTR2019-003992-21-DE Argentina;Australia;Belgium;Brazil;Canada;Chile;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003992-21-BE Argentina;Australia;Belgium;Brazil;Canada;Chile;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Lansoprazole
Huang Jinhong
2021 Phase 1 JPRN-jRCT2071210016 Japan;
Norfolk and Norwich University Hospitals NHS Foundation Trust
2021 Phase 3 NCT04965298 United Kingdom;
2020 Phase 3 EUCTR2020-000041-14-GB United Kingdom;
Lebrikizumab
Chugai Pharmaceutical Co., Ltd.
2014 Phase 2 JPRN-JapicCTI-142708 -
Hoffmann-La Roche
2013 Phase 2 NCT01872689 Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
Letairis
Gilead Sciences Incorporated
2010 - EUCTR2008-004405-34-CZ Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-004405-34-FR Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2009-011169-98-IT Austria;Czech Republic;Germany;Italy;United Kingdom;
2009 - EUCTR2008-004405-34-NL Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-004405-34-IE Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-004405-34-GB Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-004405-34-ES Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-004405-34-BE Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-004405-34-AT Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
- - EUCTR2008-004405-34-DE Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
Gilead Sciences, Inc
2009 - EUCTR2009-011169-98-GB Austria;Czech Republic;Germany;Italy;United Kingdom;
2009 - EUCTR2009-011169-98-DE Austria;Czech Republic;Germany;Italy;United Kingdom;
2009 - EUCTR2009-011169-98-AT Austria;Czech Republic;Germany;Italy;United Kingdom;
Gilead Sciences, Inc.
2011 - EUCTR2009-011169-98-CZ Austria;Czech Republic;Germany;Italy;United Kingdom;
Letermovir
Fernanda P Silveira, MD, MS
2021 Phase 2 NCT05041426 United States;
Liberase Enzyme (Roche)
Black Tie Medical, Inc.
2020 Early Phase 1 NCT04326036 United States;
Losartan
University of South Florida
2009 - NCT00879879 United States;
Low dose BIBF 1120 twice daily
Boehringer Ingelheim
2007 Phase 2 NCT00514683 Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;El Salvador;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;South Africa;Spain;Taiwan;Turkey;United Kingdom;
Low dose BIBF1120 once daily
Boehringer Ingelheim
2007 Phase 2 NCT00514683 Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;El Salvador;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;South Africa;Spain;Taiwan;Turkey;United Kingdom;
Lung Spheroid Stem Cells 100 million
University of North Carolina, Chapel Hill
2020 Phase 1 NCT04262167 United States;
Lung Spheroid Stem Cells 200 million
University of North Carolina, Chapel Hill
2020 Phase 1 NCT04262167 United States;
Lung stem cells
Shanghai East Hospital
2016 Phase 1/Phase 2 NCT02745184 China;
MG-S-2525
Metagone Biotech Inc.
2019 Phase 1 NCT03650075 Taiwan;
MRI
Bastiaan Driehuys
2015 Phase 1 NCT02478268 United States;
Macitentan
ACTELION Pharmaceuticals Ltd.
2011 - EUCTR2010-024211-13-SI Australia;Canada;Germany;Israel;Slovenia;South Africa;Spain;Sweden;Turkey;United States;
2011 - EUCTR2010-024211-13-SE Australia;Canada;Germany;Israel;South Africa;Spain;Sweden;Turkey;United States;
2011 - EUCTR2010-024211-13-ES Australia;Canada;Germany;Israel;South Africa;Spain;Sweden;Turkey;United States;
2011 - EUCTR2010-024211-13-DE Australia;Canada;Germany;Israel;South Africa;Spain;Sweden;Turkey;United States;
Actelion
2011 Phase 2 NCT01346930 -
Actelion Pharamceuticals Ltd
2010 - EUCTR2008-006054-17-IT France;Germany;Italy;Slovenia;Spain;Sweden;
Actelion Pharmaceuticals Ltd.
2009 Phase 2 EUCTR2008-006054-17-ES France;Germany;Italy;Slovenia;Spain;Sweden;
2009 - EUCTR2008-006054-17-SI France;Germany;Italy;Slovenia;Spain;Sweden;
2009 - EUCTR2008-006054-17-SE France;Germany;Italy;Slovenia;Spain;Sweden;
- - EUCTR2008-006054-17-DE France;Germany;Italy;Slovenia;Spain;Sweden;
Medical air
Queen's University
2021 Early Phase 1 NCT05052229 Canada;
Schön Klinik Berchtesgadener Land
2016 - NCT03050255 Germany;
Medical air (sham O2)
George Papanicolaou Hospital
2018 - NCT03688334 Greece;
Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)
Black Tie Medical, Inc.
2020 Early Phase 1 NCT04326036 United States;
Minocycline
University of California, Los Angeles
2006 Phase 3 NCT00203697 United States;
Montelukast
Maisonneuve-Rosemont Hospital
2011 Phase 2 NCT01432080 Canada;
Shanghai Pulmonary Hospital
2015 - ChiCTR-OOC-15005841 -
Morphine Sulfate
Royal Brompton & Harefield NHS Foundation Trust
2020 Phase 3 NCT04429516 United Kingdom;
Morphine hydrochloride
Medical University of Gdansk
2020 Phase 3 NCT04497831 -
Moxifloxacin
Respiratory Department, Peking Union Medical College Hospital
2011 - ChiCTR-TRC-12002372 China;
Mycophenolate mofetil
Peking Union Medical College Hospital
2019 Phase 4 ChiCTR1900027121 China;
N-Acetylcysteine, (NAC)
InterMune International AG.
2013 Phase 2 EUCTR2012-000564-14-GB Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
2013 - EUCTR2012-000564-14-SE Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
2013 - EUCTR2012-000564-14-IT Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
2013 - EUCTR2012-000564-14-DK Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
2013 - EUCTR2012-000564-14-DE Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
2013 - EUCTR2012-000564-14-BE Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
2013 - EUCTR2012-000564-14-AT Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
N-acetyl cysteine
University of Colorado, Denver
2022 Phase 1/Phase 2 NCT03720483 United States;
Weill Medical College of Cornell University
2020 Phase 3 NCT04300920 United States;
N-acetylcysteine
Hoffmann-La Roche
2013 Phase 2 NCT02707640 Austria;Belgium;Denmark;France;Germany;Italy;Sweden;United Kingdom;
Zambon SpA
2000 Phase 3 NCT00639496 Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
NAC
Department of Respiratory Medicine, Toho University Omori Medical Center, Tokyo
2009 - JPRN-UMIN000016045 Japan;
Grant for Research on Diffuse Lung Disease from the Ministry of Health, Labour and Welfare of Japan.
2015 - JPRN-UMIN000015508 Japan;
Shanghai Pulmonary Hospital, Tongji University School of Medicine
2020 - ChiCTR2000031386 China;
Toho University Omori Medical CenterDepartment of Respiratory Medicine
2009 - JPRN-UMIN000007663 Japan;
NALBUPHINE HYDROCHLORIDE
Trevi Therapeutics, Inc.
2019 Phase 2 EUCTR2018-004744-31-GB United Kingdom;
ND-L02-s0201
Nitto Denko Corporation
2018 Phase 2 NCT03538301 Germany;Japan;United Kingdom;United States;
ND-L02-s0201 for injection
Nitto Denko Corporation
2018 Phase 2 EUCTR2017-004919-39-DE Germany;Japan;United Kingdom;United States;
NIP292 tablet
The National Institutes of Pharmaceutical R&D Co. Ltd, China
2019 Phase 1 NCT04720443 United States;
NIP292 tablets
The National Institutes of Pharmaceutical R&D Co. Ltd, China
2019 Phase 1 NCT04720443 United States;
Nalbuphine ER
Trevi Therapeutics
2019 Phase 2 NCT04030026 United Kingdom;
Nalbuphine Extended-Realease (ER) Tablets
Trevi Therapeutics, Inc.
2019 Phase 2 EUCTR2018-004744-31-GB United Kingdom;
Nalbuphine Extended-Release (ER) Tablets
Trevi Therapeutics, Inc.
2019 Phase 2 EUCTR2018-004744-31-GB United Kingdom;
Nebivolol
Daewoong Pharmaceutical Co. LTD.
2021 Phase 1 NCT04888728 Korea, Republic of;
Nintedanib
BOEHRINGER ING.
2012 Phase 3 EUCTR2011-002766-21-IT Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
BOEHRINGER-INGELHEIM ITALIA S.P.A.
2016 Phase 3 EUCTR2015-002619-14-IT Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Boehringer Ingelheim
2021 - NCT05022784 United States;
2021 - NCT04739150 Belgium;
2021 - NCT04525547 Korea, Republic of;
2019 - NCT03958071 United States;
2019 - NCT03710824 Greece;
2018 Phase 4 NCT03717012 United States;
2016 Phase 4 NCT02788474 Australia;Belgium;Czech Republic;Czechia;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2016 Phase 4 NCT02606877 United Kingdom;
2016 Phase 3 NCT02802345 Australia;Belgium;Canada;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
2015 Phase 4 NCT02579603 Canada;France;Germany;Italy;Netherlands;United States;
2015 - NCT02607722 Japan;
2014 - NCT02230982 Brazil;
2014 - NCT02171156 United States;
2013 Phase 3 NCT01979952 Canada;Turkey;United States;
2012 Phase 3 EUCTR2011-002766-21-FI Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
2011 Phase 2 NCT01417156 Japan;
Boehringer Ingelheim Hellas
2012 Phase 3 EUCTR2011-002766-21-GR Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
Boehringer Ingelheim España S.A
2012 Phase 3 EUCTR2011-002766-21-ES Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
Boehringer Ingelheim Limited
2013 Phase 3 EUCTR2011-002766-21-IE Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
2012 Phase 3 EUCTR2011-002766-21-GB Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co. KG
2012 Phase 3 EUCTR2011-002766-21-DE Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
Boehringer Ingelheim RCV GmBH & Co KG
2010 Phase 2 EUCTR2009-013788-21-HU Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim RCV GmbH & Co KG
2012 Phase 3 EUCTR2011-002766-21-CZ Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
2010 Phase 2 EUCTR2009-013788-21-CZ Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Russian Federation;Spain;United Kingdom;
Central Japan Lung Study Grou
2017 Phase 4 JPRN-UMIN000026376 Japan;
Daewoong Pharmaceutical Co. LTD.
2021 Phase 1 NCT04888715 Korea, Republic of;
Hirosaki University Graduate School of Medicine
2016 - JPRN-UMIN000021591 Japan;
Hoffmann-La Roche
2016 Phase 4 NCT02598193 Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
IKEDA Satoshi
2019 Phase 2 JPRN-jRCTs031190119 Japan;
Intellectual Disabilities
Kanagawa Cardiovascular and Respiratory Center
2016 - JPRN-UMIN000020722 Japan;
2015 Phase 2 JPRN-UMIN000019436 Japan;
Kayamori Takefumi
2021 Phase 3 JPRN-jRCT2031210008 Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Germany;Greece;Japan;Peru;Spain;Taiwan;Turkey;USA;United Kingdom;
National Hospital Organization Ibarakihigashi National HospitalThe center of Chest Diseases and Severe Motor&
Okamoto Isamu
2017 Phase 3 JPRN-jRCTs071180049 Japan;
Research Institute for Diseases of the Chest, Kyushu University
2017 Phase 3 JPRN-UMIN000026799 Japan;
SCS Boehringer Ingelheim Ingelheim Comm.V
2012 Phase 3 EUCTR2011-002766-21-BE Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
Temple University
2019 Phase 2 NCT03562416 United States;
Unilfarma - União Internacional de Lab. Farmacêuticos, Lda
2012 Phase 3 EUCTR2011-002766-21-PT Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
Nitric Oxide
Queen's University
2021 Early Phase 1 NCT05052229 Canada;
Nivolumab
Kobe city medical center general hospital
2016 - JPRN-UMIN000022037 Japan;
None
Blade Therapeutics, Inc.
2020 Phase 2 EUCTR2019-004998-34-GB United Kingdom;
Norfolk and Norwich University Hospital NHS Foundation Trust
2014 Phase 3 EUCTR2014-004058-32-GB United Kingdom;
OFEV®
Boehringer Ingelheim
2020 - NCT04614441 Taiwan;
ORIN1001
Orinove, Inc.
2021 Phase 1 NCT04643769 United States;
Octreotide
Institut National de la Santé Et de la Recherche Médicale, France
2006 Phase 1/Phase 2 NCT00463983 France;
Ofev
BOEHRINGER-INGELHEIM ITALIA S.P.A.
2015 Phase 4 EUCTR2015-000640-42-IT Canada;France;Germany;Italy;Netherlands;United States;
F. HOFFMANN - LA ROCHE LTD.
2015 Phase 4 EUCTR2015-003280-11-IT Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
F. Hoffmann-La Roche Ltd
2016 Phase 4 EUCTR2015-003280-11-NL Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
2016 Phase 4 EUCTR2015-003280-11-DK Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
2016 Phase 4 EUCTR2015-003280-11-DE Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
Roche Farma S.A., que representa en España a F. Hoffmann-La Roche Ltd
2015 Phase 4 EUCTR2015-003280-11-ES Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
Ofev 100 mg capsule
BOEHRINGER-INGELHEIM ITALIA S.P.A.
2016 Phase 3 EUCTR2015-002619-14-IT Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Boehringer Ingelheim España, S.A.
2016 Phase 4 EUCTR2015-003148-38-ES Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-002619-14-ES Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Boehringer Ingelheim Finland Ky
2016 Phase 4 EUCTR2015-003148-38-FI Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
Boehringer Ingelheim France
2017 Phase 3 EUCTR2015-002619-14-FR Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
2016 Phase 4 EUCTR2015-003148-38-FR Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2015 Phase 4 EUCTR2015-000640-42-FR Canada;France;Germany;Italy;Netherlands;United States;
Boehringer Ingelheim Limited
2016 Phase 4 EUCTR2015-003148-38-GB Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-002619-14-GB Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co. KG
2016 Phase 4 EUCTR2015-003148-38-DE Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-002619-14-DE Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co.KG
2015 Phase 4 EUCTR2015-000640-42-DE Canada;France;Germany;Italy;Netherlands;United States;
Boehringer Ingelheim RCV GmbH & Co KG
2016 Phase 4 EUCTR2015-003148-38-PL Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2016 Phase 4 EUCTR2015-003148-38-HU Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2016 Phase 4 EUCTR2015-003148-38-CZ Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
Boehringer Ingelheim bv
2015 Phase 4 EUCTR2015-000640-42-NL Canada;France;Germany;Italy;Netherlands;United States;
SCS Boehringer Ingelheim Comm. V
2016 Phase 3 EUCTR2015-002619-14-BE Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
SCS Boehringer Ingelheim Comm. V
2016 Phase 4 EUCTR2015-003148-38-BE Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
Ofev 150 mg capsule
BOEHRINGER-INGELHEIM ITALIA S.P.A.
2016 Phase 3 EUCTR2015-002619-14-IT Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Boehringer Ingelheim España, S.A.
2016 Phase 4 EUCTR2015-003148-38-ES Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-002619-14-ES Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Boehringer Ingelheim Finland Ky
2016 Phase 4 EUCTR2015-003148-38-FI Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
Boehringer Ingelheim France
2017 Phase 3 EUCTR2015-002619-14-FR Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
2016 Phase 4 EUCTR2015-003148-38-FR Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2015 Phase 4 EUCTR2015-000640-42-FR Canada;France;Germany;Italy;Netherlands;United States;
Boehringer Ingelheim Limited
2016 Phase 4 EUCTR2015-003148-38-GB Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-002619-14-GB Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co. KG
2016 Phase 4 EUCTR2015-003148-38-DE Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-002619-14-DE Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co.KG
2015 Phase 4 EUCTR2015-000640-42-DE Canada;France;Germany;Italy;Netherlands;United States;
Boehringer Ingelheim RCV GmbH & Co KG
2016 Phase 4 EUCTR2015-003148-38-PL Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2016 Phase 4 EUCTR2015-003148-38-HU Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2016 Phase 4 EUCTR2015-003148-38-CZ Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
Boehringer Ingelheim bv
2015 Phase 4 EUCTR2015-000640-42-NL Canada;France;Germany;Italy;Netherlands;United States;
SCS Boehringer Ingelheim Comm. V
2016 Phase 3 EUCTR2015-002619-14-BE Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
SCS Boehringer Ingelheim Comm. V
2016 Phase 4 EUCTR2015-003148-38-BE Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
Omeprazole
Newcastle-upon-Tyne Hospitals NHS Trust
2014 Phase 2 NCT02085018 United Kingdom;
Omeprazole (UK licensed generic product)
Newcastle Upon Tyne Hospitals NHS Foundation Trust
2013 Phase 2 EUCTR2013-003301-26-GB United Kingdom;
Oxygen
Brigham and Women's Hospital
2011 Phase 2 NCT01214187 United States;
Department of Respiratory Medicine and Allergology, Kinki University School of Medicine
2011 - JPRN-UMIN000005098 Japan;
George Papanicolaou Hospital
2018 - NCT03688334 Greece;
Parc de Salut Mar
2019 - NCT04564664 Spain;
Schön Klinik Berchtesgadener Land
2016 - NCT03050255 Germany;
Tosei General Hospital
2009 - JPRN-UMIN000025256 Japan;
University of British Columbia
2015 - NCT02551068 Canada;
Oxymizer® compared to CNC
Klinikum Berchtesgadener Land der Schön-Kliniken
2014 - NCT02268981 Germany;
PA101
Patara Pharma
2015 Phase 2 NCT02412020 Netherlands;United Kingdom;
2015 - EUCTR2014-004025-40-NL Netherlands;United Kingdom;
2014 Phase 2 EUCTR2014-004025-40-GB Netherlands;United Kingdom;
PBI4050
Liminal BioSciences Ltd.
2015 Phase 2 NCT02538536 Canada;
PD00377 Na-salt
Vicore Pharma AB
2018 Phase 2 EUCTR2017-004923-63-GB Bulgaria;Poland;Serbia;United Kingdom;
PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714
University of Alabama at Birmingham
2020 Phase 1 NCT04362644 United States;
PIR, S-7701
INTERMUNE
2006 - EUCTR2006-000252-41-IT Italy;United Kingdom;
InterMune, Inc.
2008 Phase 3 EUCTR2007-007800-13-IE Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-007800-13-GB Australia;Belgium;Canada;France;Germany;Ireland;Italy;Poland;Spain;United Kingdom;United States;
2008 Phase 3 EUCTR2007-007800-13-ES Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-007800-13-DE Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2008 - EUCTR2007-007800-13-BE Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
PLN-74809
Pliant Therapeutics, Inc.
2020 Phase 2 NCT04396756 Australia;Belgium;Canada;Italy;Netherlands;New Zealand;United States;
2019 Phase 2 NCT04072315 United States;
PLN-74809-000
Pliant Therapeutics Inc.
2020 Phase 2 EUCTR2019-002709-23-IT Australia;Belgium;Canada;France;Germany;Italy;Netherlands;New Zealand;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002709-23-GB Australia;Belgium;Canada;France;Germany;Italy;Netherlands;New Zealand;United Kingdom;United States;
PLN-74809-020
Pliant Therapeutics Inc.
2021 Phase 2 EUCTR2019-002709-23-NL Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002709-23-DE Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;United Kingdom;United States;
PMG1015 Dose 1
Pulmongene Ltd.
2021 Phase 1 NCT05022771 Australia;
PMG1015 Dose 2
Pulmongene Ltd.
2021 Phase 1 NCT05022771 Australia;
PMG1015 Dose 3
Pulmongene Ltd.
2021 Phase 1 NCT05022771 Australia;
PMG1015 Dose 4
Pulmongene Ltd.
2021 Phase 1 NCT05022771 Australia;
PMG1015 Dose 5
Pulmongene Ltd.
2021 Phase 1 NCT05022771 Australia;
PMG1015 Dose 6
Pulmongene Ltd.
2021 Phase 1 NCT05022771 Australia;
PRIVIGEN 100mg/ml
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2018 Phase 3 EUCTR2018-002632-24-FR France;
PRM-151
Hoffmann-La Roche
2021 Phase 3 NCT04594707 Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Puerto Rico;South Africa;Spain;Sweden;Switzerland;Ukraine;United States;
2021 Phase 3 NCT04552899 Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Puerto Rico;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2015 Phase 2 NCT02550873 Belgium;Czech Republic;Czechia;Germany;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
2011 Phase 1 NCT01254409 Netherlands;United States;
Makino Ryoko
2021 Phase 3 JPRN-jRCT2051210129 Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;South Korea;Spain;Sweden;
PROMEDIOR, INC.
2015 Phase 2 EUCTR2014-004782-24-IT Belgium;Czech Republic;Czechia;France;Germany;Hungary;Italy;Netherlands;Spain;United Kingdom;United States;
Promedior inc
2015 - EUCTR2014-004782-24-NL Netherlands;
Promedior, Inc.
2016 Phase 2 EUCTR2014-004782-24-HU Belgium;Czech Republic;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
2016 Phase 2 EUCTR2014-004782-24-ES Belgium;Czech Republic;Germany;Hungary;Netherlands;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2014-004782-24-DE Belgium;Czech Republic;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
2016 Phase 2 EUCTR2014-004782-24-CZ Belgium;Czech Republic;France;Germany;Hungary;Netherlands;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2014-004782-24-BE Belgium;Czech Republic;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
Shimoda Yukiko
2022 Phase 3 JPRN-jRCT2001210001 Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;South Korea;Spain;Sweden;
PZN 8881655(RochePharma AG)
Justus Liebig Universität Giessen
2015 Phase 2 EUCTR2014-000861-32-DE Germany;
Paclitaxel
Hirosaki University Graduate School of Medicine
2016 - JPRN-UMIN000021591 Japan;
IP lung cancer study group
2012 - JPRN-UMIN000018322 Japan;
2012 - JPRN-UMIN000018248 Japan;
Katakami Nobuyuki
2013 Phase 2 JPRN-jRCTs061180046 Japan;
2013 Phase 2 JPRN-jRCTs051180149 Japan;
Lung Oncology Group in Kyushu, Japan (LOGIK)
2007 - JPRN-UMIN000015929 Japan;
Okamoto Isamu
2017 Phase 3 JPRN-jRCTs071180049 Japan;
Research Institute for Diseases of the Chest, Kyushu University
2017 Phase 3 JPRN-UMIN000026799 Japan;
Pamrevlumab
FibroGen
2020 Phase 3 NCT04419558 Brazil;Colombia;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;Ireland;Italy;Korea, Republic of;Lebanon;Mexico;Netherlands;Peru;Poland;Serbia;Spain;Switzerland;Ukraine;United Kingdom;United States;
2019 Phase 3 NCT03955146 Argentina;Australia;Chile;China;Czechia;France;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Lebanon;Netherlands;Peru;Russian Federation;Spain;Taiwan;United States;
2013 Phase 2 NCT01890265 Australia;Bulgaria;Canada;India;New Zealand;South Africa;United States;
FibroGen, Inc.
2016 Phase 2 EUCTR2014-005658-20-BG Australia;Bulgaria;Canada;India;New Zealand;South Africa;United States;
Tracy Ganske
2022 Phase 3 JPRN-jRCT2051210169 Argentina;Australia;Chile;Hong Kong;Japan;Russia;South Korea;Taiwan;United States;the People's Republic of China;
Paroxetine
Daewoong Pharmaceutical Co. LTD.
2021 Phase 1 NCT04888728 Korea, Republic of;
Pirfenidone
Beijing Kawin Technology Share-Holding Co., Ltd.
2012 Phase 2 NCT01504334 China;
Boehringer Ingelheim
2019 - NCT03958071 United States;
2016 Phase 4 NCT02606877 United Kingdom;
2015 Phase 4 NCT02579603 Canada;France;Germany;Italy;Netherlands;United States;
Bristol-Myers Squibb
2019 Phase 1 NCT03981094 United States;
Daewoong Pharmaceutical Co. LTD.
2021 Phase 1 NCT04888715 Korea, Republic of;
Department of Respiratory Medicine and Allergology, Kinki University Faculty of Medicine
2012 - JPRN-UMIN000008541 Japan;
Department of Respiratory Medicine, Toho University Omori Medical Center, Tokyo
2009 - JPRN-UMIN000016045 Japan;
Genentech, Inc.
2014 - NCT02141087 -
2011 Phase 3 NCT01366209 United States;
2008 Phase 3 NCT00662038 United States;
2006 Phase 3 NCT00287729 United States;
2006 Phase 3 NCT00287716 United States;
2003 Phase 2 NCT00080223 United States;
Grant for Research on Diffuse Lung Disease from the Ministry of Health, Labour and Welfare of Japan.
2015 - JPRN-UMIN000015508 Japan;
Hoffmann-La Roche
2017 Phase 3 NCT03208933 Russian Federation;
2017 - NCT03115619 Greece;
2016 Phase 4 NCT02598193 Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
2016 Phase 2 NCT02951429 Belgium;Canada;Czech Republic;Czechia;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 1 NCT02648048 Germany;United States;
2014 - NCT02622477 Germany;
2013 Phase 2 NCT02707640 Austria;Belgium;Denmark;France;Germany;Italy;Sweden;United Kingdom;
2013 Phase 2 NCT01872689 Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
2012 - NCT02699879 Austria;Denmark;Finland;France;Germany;Ireland;Italy;Norway;Sweden;United Kingdom;
INTERMUNE
2008 - EUCTR2007-007800-13-IT Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
Intellectual Disabilities
InterMune, Inc.
2008 Phase 3 EUCTR2007-007800-13-IE Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-007800-13-GB Australia;Belgium;Canada;France;Germany;Ireland;Italy;Poland;Spain;United Kingdom;United States;
2008 Phase 3 EUCTR2007-007800-13-ES Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-007800-13-DE Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2008 - EUCTR2007-007800-13-FR Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2008 - EUCTR2007-007800-13-BE Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2006 Phase 3 EUCTR2006-000252-41-GB Italy;United Kingdom;
2006 Phase 3 EUCTR2006-000138-11-ES Belgium;Czech Republic;Germany;Ireland;Spain;
2006 - EUCTR2006-000138-11-DE Belgium;Czech Republic;Germany;Ireland;Spain;
2006 - EUCTR2006-000138-11-CZ Belgium;Czech Republic;Germany;Ireland;Spain;
2006 - EUCTR2006-000138-11-BE Belgium;Czech Republic;Germany;Ireland;Spain;
Kanagawa Cardiovascular and Respiratory Center
2015 Phase 2 JPRN-UMIN000019436 Japan;
Kayamori Takefumi
2021 Phase 3 JPRN-jRCT2031210008 Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Germany;Greece;Japan;Peru;Spain;Taiwan;Turkey;USA;United Kingdom;
National Hospital Organization Ibarakihigashi National Hospital
2015 - JPRN-UMIN000016826 Japan;
National Hospital Organization Ibarakihigashi National HospitalThe center of Chest Diseases and Severe Motor&
North East Japan Study Group
2017 Phase 3 JPRN-UMIN000029411 Japan;
Saitama Medical University
2009 - JPRN-UMIN000005793 Japan;
Shanghai Pulmonary Hospital, Shanghai, China
2011 Phase 2 NCT02136992 -
Tianjin Medical University General Hospital
2020 Phase 4 ChiCTR2000037602 China;
West Japan Oncology Group
2012 Phase 2 JPRN-UMIN000007774 Japan;
Pirfenidone Solution for Inhalation
Avalyn Pharma, Inc.
2021 Phase 2 EUCTR2020-005103-39-PL Australia;Czech Republic;Czechia;Netherlands;New Zealand;Poland;United Kingdom;
2021 Phase 2 EUCTR2020-005103-39-CZ Australia;Czech Republic;Czechia;Netherlands;New Zealand;Poland;United Kingdom;
Pirfenidone and nintedanib
Hospices Civils de Lyon
2020 Phase 4 NCT03939520 France;
Pirfenidone or nintedanib
Hospices Civils de Lyon
2020 Phase 4 NCT03939520 France;
Pirfenidoneone
Boehringer Ingelheim
2011 Phase 2 NCT01417156 Japan;
Placebo
ASAHI KASEI PHARMA CORPORATION
2016 Phase 3 JPRN-JapicCTI-163326 -
Chugai Pharmaceutical Co., Ltd.
2014 Phase 2 JPRN-JapicCTI-142708 -
Pomalidomide (CC-4047
Stanford University
2010 Phase 2 NCT01135199 United States;
Prednisone
Hospital Universitari Vall d'Hebron Research Institute
2020 Phase 4 NCT04534478 -
Maisonneuve-Rosemont Hospital
2011 Phase 2 NCT01432080 Canada;
QAX576
Novartis Pharma Services AG
2011 - EUCTR2010-020688-18-GB United Kingdom;
Novartis Pharmaceuticals
2010 Phase 2 NCT01266135 United Kingdom;United States;
2007 Phase 2 NCT00532233 United States;
RO0220912
F. HOFFMANN - LA ROCHE LTD.
2016 Phase 2 EUCTR2015-005131-40-IT Belgium;Canada;Czech Republic;Czechia;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2015 Phase 4 EUCTR2015-003280-11-IT Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
F. Hoffmann-La Roche Ltd
2017 Phase 2 EUCTR2015-005131-40-HU Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2017 Phase 2 EUCTR2015-005131-40-CZ Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 4 EUCTR2015-003280-11-NL Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
2016 Phase 4 EUCTR2015-003280-11-DK Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
2016 Phase 4 EUCTR2015-003280-11-DE Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
2016 Phase 2 EUCTR2015-005131-40-NL Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 2 EUCTR2015-005131-40-GR Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 2 EUCTR2015-005131-40-ES Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 2 EUCTR2015-005131-40-DE Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 2 EUCTR2015-005131-40-BE Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
Roche Farma S.A., que representa en España a F. Hoffmann-La Roche Ltd
2015 Phase 4 EUCTR2015-003280-11-ES Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
RO0280296
F. Hoffmann-La Roche Ltd
2017 Phase 2 EUCTR2015-005131-40-HU Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2017 Phase 2 EUCTR2015-005131-40-CZ Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 2 EUCTR2015-005131-40-NL Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 2 EUCTR2015-005131-40-GR Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 2 EUCTR2015-005131-40-ES Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 2 EUCTR2015-005131-40-DE Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
2016 Phase 2 EUCTR2015-005131-40-BE Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
RO5490255
Chugai Pharmaceutical Co., Ltd.
2014 Phase 2 JPRN-JapicCTI-142708 -
RO5490255/F01-02
F. Hoffmann-La Roche Ltd
2014 Phase 2 EUCTR2013-001163-24-BE Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2013-001163-24-PL Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2013-001163-24-IT Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2013-001163-24-GB Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2013-001163-24-FR Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2013-001163-24-ES Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2013-001163-24-DE Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
RO7490677
F. HOFFMANN - LA ROCHE LTD.
2020 Phase 3 EUCTR2020-001429-30-IT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-000791-38-IT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
F. Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-001429-30-PT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-NO Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-NL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-HU Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-GR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-FR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-FI Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-DK Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-CZ Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-AT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-SE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-PT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-PL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-NO Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-NL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-HU Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-GR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-FI Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-DK Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-CZ Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
RO7490677/ F01-02
F. Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-001429-30-PL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
RO7490677/F01-01
F. Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-001429-30-SE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
RO7490677/F01-02
F. Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-001429-30-SE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
RO7490677/F01-03
F. Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-001429-30-SE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-PL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
RVT-1601
Respivant Sciences GmbH
2019 Phase 2 NCT03864328 Australia;Belgium;Canada;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
RVT-1601 (formerly, PA101B)
Respivant Sciences GmbH
2019 Phase 2 EUCTR2018-004447-23-NL Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004447-23-GB Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004447-23-DE Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;Turkey;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004447-23-CZ Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004447-23-BE Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
RVT-1601 (in precedenza PA101B)
Respivant Sciences, GmbH
2019 Phase 2 EUCTR2018-004447-23-IT Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
RXC007
Redx Pharma Plc
2021 Phase 1 NCT04931147 United Kingdom;
Recombinant human Pentraxin-2 (PRM-151)
F. HOFFMANN - LA ROCHE LTD.
2020 Phase 3 EUCTR2020-001429-30-IT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-000791-38-IT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
F. Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-001429-30-SE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-PT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-PL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-NO Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-NL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-HU Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-GR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-FR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-FI Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-DK Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-CZ Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001429-30-AT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-SE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-PT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-PL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-NO Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-NL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-HU Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-GR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-FI Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-DK Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000791-38-CZ Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Remicade
Academic Medical Centre
2007 - EUCTR2004-001876-37-DE Germany;
Revatio
BOEHRINGER-INGELHEIM ITALIA S.P.A.
2016 Phase 3 EUCTR2015-002619-14-IT Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Boehringer Ingelheim España, S.A.
2016 Phase 3 EUCTR2015-002619-14-ES Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Boehringer Ingelheim France
2017 Phase 3 EUCTR2015-002619-14-FR Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Boehringer Ingelheim Limited
2016 Phase 3 EUCTR2015-002619-14-GB Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co. KG
2016 Phase 3 EUCTR2015-002619-14-DE Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
SCS Boehringer Ingelheim Comm. V
2016 Phase 3 EUCTR2015-002619-14-BE Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Rituximab
Paul Szabolcs
2018 Phase 1/Phase 2 NCT03500731 United States;
University of Alabama at Birmingham
2014 Phase 2 NCT01969409 United States;
Ro 47-0203
ACTELION PHARMACEUTICALS LTD
2007 Phase 3 EUCTR2006-001183-24-SK Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-001183-24-GB Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-001183-24-ES Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2007 - EUCTR2006-001183-24-NL Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-001183-24-IE Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-001183-24-DK Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-001183-24-DE Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-001183-24-CZ Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-001183-24-AT Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2006 - EUCTR2006-001183-24-BE Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
Actelion Pharmaceuticals Ltd
2009 - EUCTR2007-001741-18-AT Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-001741-18-GB Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-001741-18-FR Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-001741-18-NL Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-001741-18-IE Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-001741-18-ES Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-001741-18-DE Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-001741-18-CZ Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-001741-18-BE Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
Routine steroid administration group
Yonsei University
2021 - NCT04996303 Korea, Republic of;
SAR100842
Horizon Therapeutics Ireland DAC
2022 Phase 2 EUCTR2021-001253-32-GR Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Italy;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States;
2022 Phase 2 EUCTR2021-001253-32-ES Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Italy;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States;
SAR156597
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
2015 Phase 2 EUCTR2014-003933-24-IT Czech Republic;Denmark;France;Germany;Greece;Italy;Portugal;Spain;United Kingdom;
Sanofi
2015 Phase 2 NCT02345070 Argentina;Australia;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States;
2012 Phase 1/Phase 2 NCT01529853 Belgium;Canada;Chile;Mexico;Spain;United States;
sanofi-aventis recherche & développement
2016 Phase 2 EUCTR2014-003933-24-PT Argentina;Australia;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003933-24-GR Argentina;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003933-24-GB Argentina;Australia;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003933-24-FR Argentina;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003933-24-ES Argentina;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003933-24-DK Argentina;Australia;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003933-24-DE Argentina;Australia;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003933-24-CZ Argentina;Australia;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States;
SEPTRIN
Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI)
2013 Phase 3 EUCTR2012-005409-38-ES Spain;
SHR-1906
Guangdong Hengrui Pharmaceutical Co., Ltd
2021 Phase 1 NCT04986540 -
SM04646
Samumed LLC
1900 Phase 2 NCT03591926 Australia;New Zealand;
SODIUM CROMOGLICATE
Respivant Sciences GmbH
2019 Phase 2 EUCTR2018-004447-23-NL Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004447-23-GB Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004447-23-DE Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;Turkey;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004447-23-CZ Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004447-23-BE Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
Respivant Sciences, GmbH
2019 Phase 2 EUCTR2018-004447-23-IT Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
Salbutamol
Royal Brompton & Harefield NHS Foundation Trust
2012 Phase 1 NCT01457261 United Kingdom;
Saracatinab
National Jewish Health
2020 Phase 1/Phase 2 NCT04598919 United States;
Septrin
University of East Anglia
2007 - EUCTR2007-002324-15-GB United Kingdom;
Sildenafil
Boehringer Ingelheim
2016 Phase 3 NCT02802345 Australia;Belgium;Canada;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
F. HOFFMANN - LA ROCHE LTD.
2016 Phase 2 EUCTR2015-005131-40-IT Belgium;Canada;Czech Republic;Czechia;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
Hoffmann-La Roche
2016 Phase 2 NCT02951429 Belgium;Canada;Czech Republic;Czechia;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
Rabin Medical Center
2011 Phase 4 NCT01382368 Israel;
University of California, Los Angeles
2007 Phase 4 NCT00625079 United States;
VA Office of Research and Development
2006 Phase 2 NCT00359736 United States;
Sildenafil (50 mg)
National Heart, Lung, and Blood Institute (NHLBI)
2004 Phase 2 NCT00352482 United States;
Sildenafil Citrate
Duke University
2007 Phase 3 NCT00517933 United States;
Sildenafil and Losartan
Alicia Gerke
2009 Phase 2/Phase 3 NCT00981747 United States;
Simtuzumab
Gilead Sciences
2013 Phase 2 NCT01769196 Australia;Belgium;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Switzerland;United Kingdom;United States;
2012 Phase 2 NCT01759511 United States;
Gilead Sciences, Inc.
2013 Phase 2 EUCTR2012-001571-36-GB Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2012-001571-36-CZ Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2012-001571-36-BE Australia;Belgium;Canada;Czech Republic;France;Germany;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Poland;Spain;Switzerland;United Kingdom;United States;
2013 - EUCTR2012-001571-36-PL Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2013 - EUCTR2012-001571-36-IT Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2013 - EUCTR2012-001571-36-ES Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2013 - EUCTR2012-001571-36-DE Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
Sirolimus
University of Virginia
2011 - NCT01462006 United States;
Sivelestat
Japanese Northern East Area Thoracic Surgery Study Group (JNETS)
2013 Phase 3 JPRN-UMIN000021109 Japan;
Sterile Normal Saline for Intravenous Use
Black Tie Medical, Inc.
2020 Early Phase 1 NCT04326036 United States;
Steroid pulse therapy group
Yonsei University
2021 - NCT04996303 Korea, Republic of;
Sub-Study: Nintedanib
FibroGen
2013 Phase 2 NCT01890265 Australia;Bulgaria;Canada;India;New Zealand;South Africa;United States;
Sub-Study: Pirfenidone
FibroGen
2013 Phase 2 NCT01890265 Australia;Bulgaria;Canada;India;New Zealand;South Africa;United States;
Sulphamethoxazole
Norfolk and Norwich University Hospital NHS Foundation Trust
2014 Phase 3 EUCTR2014-004058-32-GB United Kingdom;
Symbicort
Maisonneuve-Rosemont Hospital
2011 Phase 2 NCT01432080 Canada;
TBC
Nitto Denko Corporation
2018 Phase 2 EUCTR2017-004919-39-DE Germany;Japan;United Kingdom;United States;
TD-1058
Theravance Biopharma
2020 Phase 1 NCT04589260 United Kingdom;
TD139
Galecto Biotech AB
2019 Phase 2 EUCTR2018-002664-73-IT Belgium;Canada;France;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002664-73-GB Belgium;Canada;France;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002664-73-FR Belgium;Canada;France;Germany;Israel;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002664-73-ES Belgium;Canada;France;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States;
TNX-650, rhuMAb anti-IL13, aIL-13, MILR1444A
F. Hoffmann-La Roche Ltd
2014 Phase 2 EUCTR2013-001163-24-BE Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2013-001163-24-PL Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2013-001163-24-IT Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2013-001163-24-GB Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2013-001163-24-FR Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2013-001163-24-ES Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2013-001163-24-DE Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
TR0311
Trevi Therapeutics, Inc.
2019 Phase 2 EUCTR2018-004744-31-GB United Kingdom;
TRACLEER
Actelion Pharmaceuticals LTD
2006 - EUCTR2006-001183-24-IT Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
Actelion Registration Ltd
2008 - EUCTR2007-001741-18-IT Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
TRK-250
Toray Industries, Inc
2018 Phase 1 NCT03727802 United States;
Tacrolimus
Peking Union Medical College Hospital
2019 Phase 4 ChiCTR1900027121 China;
Taladegib
Endeavor Biomedicines, Inc.
2021 Phase 2 NCT04968574 Australia;Malaysia;
Tetrandrine
The First People's Hospital of Yancheng
2020 Phase 0 ChiCTR2000030400 China;
Tetrathiomolybdate
University of Michigan
2003 Phase 1/Phase 2 NCT00189176 United States;
Thalidomide
Johns Hopkins University
2007 Phase 3 NCT00600028 United States;
2003 Phase 2 NCT00162760 United States;
Thalidomide Pharmion
University of Nottingham
2011 - EUCTR2010-023828-24-GB United Kingdom;
The Standard Steroid Treatment, Plasma Exchange and rituximab
University of Pittsburgh
2012 Phase 2 NCT01524068 United States;
Thiotepa
Paul Szabolcs
2018 Phase 1/Phase 2 NCT03500731 United States;
Tiotropium
Saitama Medical University
2009 - JPRN-UMIN000005793 Japan;
Tipelukast
MediciNova
2016 Phase 2 NCT02503657 United States;
Tracleer
ACTELION PHARMACEUTICALS LTD
2007 Phase 3 EUCTR2006-001183-24-SK Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-001183-24-GB Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-001183-24-ES Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2007 - EUCTR2006-001183-24-NL Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-001183-24-IE Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-001183-24-DK Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-001183-24-DE Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-001183-24-CZ Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-001183-24-AT Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2006 - EUCTR2006-001183-24-BE Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
- Phase 3 EUCTR2006-001183-24-FR Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom;
Actelion Pharmaceuticals Ltd
2009 - EUCTR2007-001741-18-AT Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-001741-18-GB Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-001741-18-FR Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-001741-18-NL Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-001741-18-IE Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-001741-18-ES Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-001741-18-DE Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-001741-18-CZ Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-001741-18-BE Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
Royal Brompton and Harefield NHS Trust
2007 - EUCTR2007-001645-17-GB United Kingdom;
Traditional Chinese Medicine Formulation
Xuzhou Traditional Chinese Medicine Hospital
2018 - NCT03711435 China;
Tralokinumab
MedImmune LLC
2012 Phase 2 NCT01629667 Australia;Canada;Israel;Korea, Republic of;Peru;United States;
Tralokinumab cohort 1
AstraZeneca
2014 Phase 2 NCT02036580 Japan;
Tralokinumab cohort 2
AstraZeneca
2014 Phase 2 NCT02036580 Japan;
Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
AstraZeneca
- Phase 2 JPRN-JapicCTI-142452 -
Treatment as Usual (TAU)
University of Alabama at Birmingham
2018 Phase 2 NCT03286556 United States;
Treprostinil
Rajan Saggar
2008 Phase 2 NCT00705133 United States;
Treprostinil Ultrasonic Nebulizer
United Therapeutics
2022 Phase 3 NCT05255991 -
2022 Phase 3 NCT04905693 -
2021 Phase 3 NCT04708782 United States;
Treprostinil sodium for inhalation
Lung Biotechnology PBC
2008 Phase 2 NCT00703339 United States;
Trimethoprim
Norfolk and Norwich University Hospital NHS Foundation Trust
2014 Phase 3 EUCTR2014-004058-32-GB United Kingdom;
VAY736
Novartis Pharma AG
2018 Phase 2 EUCTR2017-002667-17-IT Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002667-17-IE Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002667-17-GB Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002667-17-FR Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002667-17-DE Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
Novartis Pharmaceuticals
2017 Phase 2 NCT03287414 Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
VRP700
Verona Pharma plc
2013 - EUCTR2012-005794-31-GB United Kingdom;
Valganciclovir
Fernanda P Silveira, MD, MS
2021 Phase 2 NCT05041426 United States;
Vanderbilt University Medical Center
2018 Phase 1 NCT02871401 United States;
Vasoactive intestinal peptide
Mondobiotech Laboratories Anstalt
2006 - EUCTR2006-002174-22-DE Germany;
Vismodegib
Hoffmann-La Roche
2016 Phase 1 NCT02648048 Germany;United States;
2014 Phase 2 NCT02168530 Australia;France;Germany;Israel;Korea, Republic of;Mexico;Peru;United States;
Warfarin
Duke University
2009 Phase 3 NCT00957242 United States;
ZL-2102
Zai Lab Pty. Ltd.
2015 Phase 1 NCT02397005 Australia;
ZSP1603
Guangdong Raynovent Biotech Co., Ltd
2021 Phase 1/Phase 2 NCT05119972 China;
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
2018 Phase 1 NCT03619616 China;
Zileuton
University of Michigan
2001 Phase 2 NCT00262405 United States;
Ziritaxestat
Galapagos NV
2019 Phase 3 EUCTR2018-001406-29-HU Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
2019 Phase 3 EUCTR2018-001405-87-GR Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001405-87-GB Australia;Belgium;Brazil;Chile;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001405-87-DE Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001405-87-CZ Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001405-87-BE Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2018-001406-29-PL Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
2018 Phase 3 EUCTR2018-001405-87-DK Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
[18F]-FBA-A20FMDV2
GlaxoSmithKline
2017 Phase 1 NCT03069989 United Kingdom;
[18F]FP-R01-MG-F2
Stanford University
2017 Early Phase 1 NCT03183570 United States;
[68Ga]CBP8
Massachusetts General Hospital
2018 Phase 1 NCT03535545 United States;